

25 e-mail: christian.loew@embl-hamburg.de

26

27 **Abstract**

28 Apicomplexan parasites, such as *Plasmodium falciparum* and *Toxoplasma gondii*, traverse
29 the host tissues and invade the host cells exhibiting a specific type of motility called gliding.
30 The molecular mechanism of gliding lies in the actin-myosin motor localized to the
31 intermembrane space between the plasma membrane and inner membrane complex (IMC) of
32 the parasites. Myosin A (MyoA) is a part of the glideosome, a large multi-protein complex,
33 which is anchored in the outer membrane of the IMC. MyoA is bound to the proximal essential
34 light chain (ELC) and distal myosin light chain (MLC1), which further interact with the
35 glideosome associated proteins GAP40, GAP45 and GAP50. Whereas structures of several
36 individual glideosome components and small dimeric complexes have been solved, structural
37 information concerning the interaction of larger glideosome subunits and their role in
38 glideosome function still remains to be elucidated. Here, we present structures of a *T. gondii*
39 trimeric glideosome sub complex composed of a myosin A light chain domain with bound
40 MLC1 and TgELC1 or TgELC2. Regardless of the differences between the secondary
41 structure content observed for free *P. falciparum* PfELC and *T. gondii* TgELC1 or TgELC2,
42 the proteins interact with a conserved region of TgMyoA to form structurally conserved
43 complexes. Upon interaction, the essential light chains undergo contraction and induce
44 α -helical structure in the myosin A C-terminus, stiffening the myosin lever arm. The complex
45 formation is further stabilized through binding of a single calcium ion to *T. gondii* ELCs. Our
46 work provides an important step towards the structural understanding of the entire glideosome
47 and uncovering the role of its members in parasite motility and invasion.

48

49

50

51 **Author summary**

52 Apicomplexans, such as *Toxoplasma gondii* or the malaria agent *Plasmodium falciparum*, are
53 small unicellular parasites that cause serious diseases in humans and other animals. These
54 parasites move and infect the host cells by a unique type of motility called gliding. Gliding is
55 empowered by an actin-myosin molecular motor located at the periphery of the parasites.
56 Myosin interacts with additional proteins such as essential light chains to form the glideosome,
57 a large protein assembly that anchors myosin in the inner membrane complex. Unfortunately,
58 our understanding of the glideosome is insufficient because we lack the necessary structural
59 information. Here we describe the first structures of trimeric glideosome sub complexes of *T.*
60 *gondii* myosin A bound to two different light chain combinations, which show that *T. gondii* and
61 *P. falciparum* form structurally conserved complexes. With an additional calcium-free complex
62 structure, we demonstrate that calcium binding does not change the formation of the
63 complexes, although it provides them with substantial stability. With additional data, we
64 propose that the role of the essential light chains is to enhance myosin performance by
65 inducing secondary structure in the C-terminus of myosin A. Our work represents an important
66 step in unveiling the gliding mechanism of apicomplexan parasites.

67 Introduction

68 *Apicomplexa* are a phylum of intracellular, parasitic, single cell eukaryotes with a high medical
69 and agricultural relevance. For instance, *Plasmodium species* is the causative agent of
70 malaria, that leads to 414.000 deaths per year [1]. The number of malaria cases increased or
71 stopped decreasing in several African countries in the last few years due to the emergence of
72 new drug-resistant strains [1]. Another apicomplexan parasite, *Toxoplasma gondii*, is
73 responsible for toxoplasmosis in humans [2]. Although more than 30% of the world population
74 is thought to be infected with *T. gondii* causing no obvious symptoms, the infections can cause
75 severe damage in immunocompromised patients and pregnant women [2]. Proliferation and
76 transmission of these obligate endoparasites in their host organisms rely on efficient cell
77 invasion [3]. This active process is based on the motility of the parasite that is referred as
78 gliding and is empowered by an actin/myosin motor [4,5]. This motor is localized within the
79 intermembrane space between the parasite's plasma membrane and inner membrane
80 complex (IMC), an additional double-layer of membranes that is unique for these single cell
81 organisms [6]. The IMC provides stability to invasion competent stages of the parasite and
82 functions as an anchor for the actin/myosin motor. While motility is achieved by the interaction
83 of the myosin with actin filaments, the myosin is linked to the IMC by a membrane-embedded
84 multi-protein complex referred to as the glideosome [7–9] (Fig 1A).

85 According to the current model, the apicomplexan glideosome is composed of six proteins:
86 myosin MyoA, essential light chain ELC, myosin light chain MLC1, and the glideosome-
87 associated proteins GAP40, GAP45 and GAP50 [7,8,10]. MyoA is an unusual small myosin
88 protein of the unconventional myosin class XIV [11,12], missing the typical myosin tail domain
89 and binding the two light chains at the C-terminal myosin neck region [13,14]. MLC1 (in
90 *P. falciparum*: myosin A tail-interacting protein, MTIP) binds at the very C-terminus of MyoA,
91 while ELC is expected to interact with the C-terminus of MyoA upstream of MLC1 [15]. Two
92 ELC homologs recognizing the same MyoA region, termed TgELC1 and TgELC2, were
93 identified in *T. gondii* [16], whereas only one PfELC homolog is known in *P. falciparum* [14,17].
94 Myosin together with its light chains and the glideosome associated protein 45 (GAP45) has

95 been shown to form a pre-complex in the earlier stages of intracellular parasite development
96 [7], which subsequently assembles with the remaining glideosome members (GAP40 and
97 GAP50). Both MLC1 (MTIP) and GAP45 use their N-terminal myristoylation and palmitoylation
98 sites to anchor in the outer IMC membrane [18]. GAP45 is essential for the correct localization
99 of MyoA with its light chains and GAP45 depletion leads to impairment of the host cell invasion
100 [10]. Depletion of GAP40 or GAP50 changes the morphology of the parasites and the integrity
101 of the IMC and thereby also alters the localization of MyoA and the light chains [19]. Thus,
102 GAPs do not only serve as an anchor of the glideosome but provide stability and integrity to
103 the IMC. Indeed, the localization of GAP40 is restrained to distinct foci evenly distributed along
104 the co-localized tubulin, suggesting that the glideosome is further interconnected within the
105 network of IMC proteins and in turn attaches to the cytosolic tubulin network [19,20].
106 Structural information on individual members and subcomplexes of the glideosome are limited
107 and the architecture of the entire glideosome is elusive. So far, only the structures of
108 *P. falciparum* PfGAP50 soluble domain [21], a *T. gondii* dimeric complex between the TgMyoA
109 C-terminus and MLC1 [15], a homologous dimeric complex in *P. falciparum* between PfMyoA
110 C-terminus and MTIP [22], and the motor domains of the *T. gondii* TgMyoA [23] and *P.*
111 *falciparum* PfMyoA [24] are available (S1 Table).
112 Here we present crystal structures of trimeric complexes of *T. gondii* composed of MLC1, the
113 C-terminus of MyoA and TgELC2 or TgELC1 in both calcium-bound and -free forms as well
114 as the X-ray crystal structure and NMR solution structures of the N-terminal domain of *P.*
115 *falciparum* PfELC. We provide a thorough characterization of all identified interaction surfaces
116 and demonstrate that the ELCs bind to a conserved binding site on MyoA. Furthermore, we
117 show that the N-terminal domain of isolated PfELC is structured whereas its C-terminus is
118 more disordered than its *T. gondii* homologs. However, ELCs from both *P. falciparum* and *T.*
119 *gondii* mutually induce the structure with the disordered MyoA C-terminus to assemble into
120 structurally conserved complexes.

121

122 **Results**

123 **PfELC folds into a calmodulin-like N-terminal domain with a disordered C-terminus**

124 Crystal structures of *T. gondii* and *P. falciparum* MyoA [23,24] as well as structures of their
125 distal light chains MLC1 (MTIP) [15,22] have already been determined. To shed light on the
126 architecture and folding of the recently identified proximal essential light chains (ELCs) we
127 studied their structure in the context of their interaction partners. Analysis of the sequences of
128 the two *T. gondii* myosin essential light chains TgELC1 and TgELC2 and the *P. falciparum*
129 homolog PfELC indicates likely structural differences for the latter. TgELC1 and TgELC2 share
130 a high degree of sequence identity (44.4%) and similarity (65.2%), whereas PfELC is
131 significantly less similar to the *T. gondii* ELCs, with 20.3% identity and 40.6% similarity to
132 TgELC1 (Fig 1C). Likewise, the disorder probability differs between the *T. gondii* and *P.*
133 *falciparum* essential light chain homologs (S1A Fig). To study the structural differences, we
134 recombinantly expressed N-terminally His-tagged ELCs in *E. coli* (Fig 1B) and purified them
135 to homogeneity. In spite of similar molecular weight, PfELC and TgELC2 display distinct
136 elution profiles when subjected to size-exclusion chromatography (SEC). PfELC elutes earlier
137 compared to TgELC2 (Fig 2A), suggesting differences in the hydrodynamic radius of these
138 constructs. Small angle X-ray scattering (SAXS) measurements further confirm that PfELC
139 does indeed have a larger overall size in solution compared to that of TgELC2, with the
140 respective radii of gyration (R_g) being 2.71 ± 0.05 nm and 2.14 ± 0.05 nm (Fig S1B-D, Table 1
141 and S2 Table). The SAXS data also provide evidence that the increased R_g of PfELC likely
142 results from conformational flexibility, as the peak of PfELC in the dimensionless Kratky plot
143 is broader and shifted towards higher angles compared to that of TgELC2 (Fig S1C, S2 Table).
144 This finding is corroborated by the observed secondary structure content for PfELC derived
145 from circular dichroism spectroscopy, showing that PfELC has lower α -helical and higher
146 random coil content compared to TgELC2 (Fig 2B, Table 1). In order to map structured
147 elements and disordered regions of PfELC, we performed triple-resonance NMR experiments
148 that facilitated the near complete assignment of the amide backbone resonances (Fig. S1E).

149 Secondary structure elements were determined from chemical shifts and the dynamics of the
150 PfELC backbone was probed using heteronuclear NOEs ($\{^1\text{H}\}$ - ^{15}N NOE). This ^{15}N based
151 dynamics experiment allows to distinguish between rigid ($\{^1\text{H}\}$ - ^{15}N NOE > 0.7, secondary
152 structure elements), somewhat flexible ($\{^1\text{H}\}$ - ^{15}N NOE ~ 0.5-0.7, loops and turns) and
153 extremely flexible ($\{^1\text{H}\}$ - ^{15}N NOE < 0.5, unfolded/ random coil) regions of the protein.
154 This analysis on PfELC revealed that the protein contains an α -helical structure in the
155 N-terminal domain, while the C-terminal part is disordered in isolation as evident by the low
156 heteronuclear NOEs for this region (Fig 2C). Based on this finding, we expressed and purified
157 an N-terminal fragment of PfELC (amino acids 1-74, PfELC-N; see Fig 1B) and determined its
158 structure by both X-ray crystallography to 1.5 Å resolution (Fig 2E, Table 2) and by NMR
159 spectroscopy (Fig 2F, S3 Table). The ten lowest energy NMR structures superimpose with an
160 average backbone RMSD of 0.87 Å and an all-atom RMSD of 1.23 Å. The lowest energy NMR
161 conformer is very similar to the crystal structure, with a backbone RMSD of 1.4 Å over residues
162 1-68. The N-terminal domain of PfELC has a typical calmodulin fold with two EF-hands formed
163 by two helix-loop-helix motifs. EF-hands typically have the capacity to bind calcium [25] but
164 here, both EF-hands lack the canonical calcium binding residues and therefore are not able
165 to bind calcium as evident in the determined crystal structure. PfELC-N crystallized as a dimer
166 with a covalently linked disulfide bridge between cysteine 19 residues on both protein chains
167 (S1F Fig). However, in solution, the protein is monomeric, as shown on non-reducing
168 SDS-PAGE (S1G Fig) and by SAXS (the scattering computed from the crystal structure yields
169 a good fit with discrepancy $X^2=1.37$ to the SAXS data, Fig 2D, S2 Table), and cysteine 19 is
170 reduced, as probed by the indicative NMR $^{13}\text{C}\beta$ shift. A comparison of the crystal structure
171 with the NMR structure highlights that the loop of the first EF hand (residues 16-22) and the
172 third helix (residues 40-47) displays the highest degree of flexibility, in agreement with the
173 heteronuclear NOE experiment (Fig 2C), while the position of the other loops agrees well
174 between the crystal and the NMR structure (Fig 2E-F). In general, the assigned backbone
175 resonances in the NMR spectra superimpose for both full-length protein PfELC and the
176 N-terminal domain, highlighting that the N-terminal domain maintains the same structure in

177 both constructs (S1E Fig). These results show that isolated PfELC is monomeric in solution
 178 with a calmodulin-like N-terminal fold and a disordered C-terminal region.

179

180 **Table 1. Biophysical characterization and comparison of PfELC and TgELC2.**

	SEC data	CD data			SAXS data		
	Elution volume (ml)	α helix	β sheet	random	R _g (nm)	MW (kDa)	D _{max} (nm)
TgELC2	2.41	41%	15%	45%	2.15	17.0	6.73
PfELC	2.18	34%	16%	51%	2.83	16.3	9.50

181

182 **Table 2. X-ray data collection and refinement statistics**

	PfELC-N	Complex 1	Complex 1f	Complex 2
Data collection				
Beamline	PETRA III P14	PETRA III P13	PETRA III P13	PETRA III P13
Wavelength (Å)	1.0332	1.0332	0.9762	1.0332
Space group	P 21 21 21	P 41	P 41	I 21 21 21
Unit cell				
a, b, c (Å)	30.24, 57.51, 86.34	87.32, 87.32, 56.75	86.13, 86.13, 53.7	84.63, 93.48, 108.15
α, β, γ (°)	90, 90, 90	90, 90, 90	90, 90, 90	90, 90, 90
Resolution (Å)	47.86 - 1.50 (1.55 - 1.50)	47.58 - 2.39 (2.48 - 2.39)	40.94 - 2.00 (2.07 - 2.00)	40.96 - 2.30 (2.38 - 2.30)
R _{merge}	0.03382 (0.495)	0.106 (1.599)	0.0431 (1.35)	0.08044 (1.007)
I/ σ I	17.68 (2.06)	19.06 (1.40)	31.02 (1.74)	13.84 (1.79)
CC1/2	0.999 (0.892)	0.999 (0.718)	0.999 (0.718)	0.999 (0.575)
Completeness (%)	99.0 (98.0)	99.9 (99.7)	99.9 (99.4)	99.9 (99.9)
Total no. reflections	104329 (9981)	226789 (23610)	373831 (34891)	124597 (12474)
Multiplicity	4.2 (4.2)	13.3 (13.7)	13.5 (12.9)	6.4 (6.6)
Wilson B-factor (Å ²)	24.12	58.03	48.32	47.21
Refinement				
R _{work} / R _{free}	0.167 / 0.193	0.189 / 0.231	0.190 / 0.225	0.186 / 0.219
No. atoms	1319	2523	2610	2687
Protein	1126	2457	2458	2578
Ligands	n.a.	2	5	33
Solvent	193	64	147	76
B-factors	36.5	78.2	65.4	65.3
Proteins	34.8	78.3	65.4	65.0
Ligands	n.a.	96.6	111	94.2
Solvent	46.5	72.8	63.2	62.6
R.m.s. deviations				
Bond lengths (Å)	0.013	0.008	0.003	0.007
Angles (°)	1.16	0.97	0.60	0.87
Ramachandran				
Favored (%)	100	98.7	98.7	98.7
Outliers (%)	0	0.33	0.33	0.33
Clash score	1.8	4.4	7.1	10.3
PDB accession no.	6tj4	6tj5	6tj6	6tj7

183

184 **Essential light chains bind conserved sequence of MyoA**

185 Both *T. gondii* ELCs (TgELC1 and TgELC2) as well as *P. falciparum* PfELC have been
 186 previously shown to bind to the C-terminus of MyoA [13,14,17]. Whereas for PfELC, two
 187 binding sites of the PfMyoA C-terminus (PfMyoA residues 786-803 and 801-818; Fig 3A) were

188 identified [14], only one binding site was experimentally confirmed for TgELCs (TgMyoA
189 775-795; Fig 3A) [15,16]. To investigate these interactions further, we measured the binding
190 affinity of TgELC1, TgELC2 and PfELC to peptides corresponding to the proposed MyoA
191 binding sites.

192 Strikingly, we could not monitor any binding of PfELC to the previously described binding sites
193 but observed precipitation upon mixing PfELC with the respective peptides. The TgELC1/2
194 binding site is highly conserved between *T. gondii* TgMyoA and *P. falciparum* PfMyoA,
195 therefore we hypothesized that PfELC could bind the homologous conserved region (see
196 Fig 3A) and extended the PfMyoA peptide accordingly. However, precipitation occurred again
197 and we speculated that the presence of MTIP bound to PfMyoA is a prerequisite for binding
198 of PfELC. In agreement with this hypothesis, previous reports have shown that PfELC can be
199 co-purified with full-length MyoA only in the presence of MTIP from insect cells [17]. To
200 determine the affinity of PfELC via isothermal titration calorimetry we first formed a complex
201 between MTIP and the PfMyoA neck region peptide (PfMyoA-C, residues 775-816; S2 Fig and
202 see Fig 3B) and then titrated in PfELC. PfELC bound to MTIP and PfMyoA-C with an affinity
203 of 120 ± 18 nM (Fig 3E and Table 3). Interestingly, we observed the opposite behavior for the
204 *T. gondii* light chains. The *T. gondii* MTIP homolog, MLC1, precipitated upon interacting with
205 TgMyoA-C (residues 777-818, see Fig 3B), but both TgELC1 and TgELC2 bound
206 TgMyoA-C^{ELC} (residues 777-799, see Fig 3B) with high affinity (42 ± 6.7 nM and 160 ± 19 nM,
207 respectively) (Fig 3C-D and Table 3).

208 Finally, we were able to reconstitute the trimeric complex with both TgELC1 and TgELC2, by
209 first forming the dimeric complex between TgELC1 or TgELC2 and TgMyoA-C and then
210 adding MLC1. MLC1 bound the preformed complex of TgELC1 or TgELC2 and TgMyoA-C
211 with high affinity (4.7 ± 2.5 nM and 0.6 ± 0.1 nM, respectively) (Fig F-G and Table 3). In
212 conclusion, *T. gondii* TgELC1 and TgELC2 need to interact with TgMyoA-C *in vitro* first and
213 only then MLC1 can assemble into the trimeric complex. In *P. falciparum*, MTIP first interacts
214 with the C-terminus of PfMyoA and only after that, PfELC is able to bind and form the trimeric

215 complex. All ELC homologs bind a highly conserved sequence stretch at the C-terminus of
 216 MyoA (Fig 3A).

217

218 **Table 3. Overview of thermodynamic constants measured by ITC.**

Dimeric interactions					
Protein (cell)	MyoA peptide (syringe)	Molar ratio	K_d (nM)	ΔH (kcal/mol)	$-T\Delta S$ (kcal/mol)
MTIP	PfMyoA-C ^{ELC}	0.71 ± 0.01	320 ± 57	-15 ± 0.4	5.5
TgELC1	TgMyoA-C ^{ELC}	1.05 ± 0.01	42 ± 6.7	-13 ± 0.2	3.2
TgELC2	TgMyoA-C ^{ELC}	0.87 ± 0.01	160 ± 19	-17 ± 0.2	7.4
TgELC2 ^{E10A}	TgMyoA-C ^{ELC}	0.79 ± 0.01	190 ± 25	-17 ± 0.3	8.2
TgELC2 ^{D16A}	TgMyoA-C ^{ELC}	0.80 ± 0.01	280 ± 30	-19 ± 0.3	9.7
TgELC2 ^{F79A}	TgMyoA-C ^{ELC}	0.84 ± 0.01	280 ± 34	-18 ± 0.3	9.5
TgELC2 ^{S101A}	TgMyoA-C ^{ELC}	0.88 ± 0.02	280 ± 85	-18 ± 0.8	9.3
TgELC2 ^{E10A+H110A}	TgMyoA-C ^{ELC}	0.75 ± 0.02	1100 ± 220	-21 ± 0.9	12

Trimeric interactions					
Pre-complex with MyoA-C (cell)	Protein (syringe)	Molar ratio	K_d (nM)	ΔH (kcal/mol)	$-T\Delta S$ (kcal/mol)
MTIP	PfELC	0.83 ± 0.01	120 ± 18	-13.0 ± 0.25	3.6
TgELC1	MLC1	0.92 ± 0.01	4.7 ± 2.5	-39.1 ± 0.76	28
TgELC2	MLC1	0.81 ± 0.01	0.6 ± 0.1	-47.6 ± 0.12	35
TgELC2 ^{R17A}	MLC1	0.92 ± 0.01	4.6 ± 0.4	-49.7 ± 0.17	38
TgELC2 ^{E22A}	MLC1	0.92 ± 0.01	5.2 ± 1.9	-45.9 ± 0.65	35
TgELC2	MLC1 ^{K168A}	0.79 ± 0.01	1.2 ± 0.8	-47.7 ± 0.24	36
TgELC2	MLC1 ^{Q169A}	0.89 ± 0.01	2.3 ± 1.9	-48.8 ± 0.50	37
TgELC2	MLC1 ^{N172A}	0.84 ± 0.01	4.3 ± 4.3	-41.6 ± 0.92	30

219 The thermodynamic parameters were fitted by a one site binding model with the MicroCal
 220 PEAQ-ITC Analysis Software.

221

222 **Essential light chains bind MyoA in a compact conformation and induce an α -helical**
 223 **structure**

224 Previous reports have shown that the presence of *P. falciparum* and *T. gondii* essential light
 225 chains increases the speed of the myosin A motor twofold [14,16,17]. To understand the
 226 functional role of ELCs on a molecular level, we characterized TgELC2 in a free and bound
 227 state in complex with TgMyoA-C^{ELC} (see Fig 3B). On size exclusion chromatography, the
 228 dimeric complex of TgELC2 and TgMyoA-C^{ELC} elutes later than TgELC2 alone, indicating that

229 the overall size of TgELC2 decreases upon binding of TgMyoA-C^{ELC} (Fig 4A). Indeed, the
230 parameters extracted from the SAXS measurements indicate compaction upon formation of
231 the complex (see S2 Table and Fig 4B-C). Before addition of the MyoA-C^{ELC}, the flexible
232 nature of TgELC2 relative to the complex is observed as a broad peak shifted to high angles
233 in the dimensionless Kratky plot. Upon complex formation, the peak becomes narrower and
234 shifts to lower angles, an indication of macromolecular compaction (Fig 4B, also see
235 S3A-B Fig). In agreement, the R_g calculated from the experimental data by Guinier analysis
236 [26] decreases from 2.15 nm to 1.73 nm upon binding and the particle distance distribution
237 changes accordingly, with the maximum size decreasing from 6.7 nm for TgELC2 to 5.5 nm
238 for the complex (S2 Table and Fig 4C). These data suggest that the flexible TgELC2 protein
239 undergoes a conformational change upon binding to TgMyoA C-terminus, adopting a compact
240 structure, similarly to what was reported for the MTIP-PfMyoA interaction [22]. In all previously
241 solved myosin structures, the myosin neck regions fold in a long α helix, tightly bound by their
242 light chains [27]. This rigid conformation allows the neck region to act as the lever arm of
243 myosin and its stiffness directly correlates with the myosin step size and speed [28–30].
244 However, both TgMyoA-C as well as PfMyoA-C are unfolded or partially unfolded in isolation
245 (S3C Fig). Indeed, the C-terminal amino acid residues of the recently published TgMyoA [23]
246 and PfMyoA [24] motor domain structures could not be resolved, likely due to their intrinsically
247 disordered nature. We hypothesized that the essential light chains can induce α -helical
248 structure in MyoA upon binding, therefore we measured circular dichroism of TgMyoA-C^{ELC}
249 and TgELC2 in isolation and in the complex (Fig 4D). The data show that isolated
250 TgMyoA-C^{ELC} is unstructured and TgELC2 has a predominantly α -helical fold. However, the
251 circular dichroism spectrum of the dimeric complex has a significantly higher α -helical content
252 than the sum of the spectra of the two individual components, as shown by a lower ellipticity
253 at 222 nm and a higher ellipticity at 195 nm, suggesting that the content of the α -helical
254 secondary structure increased upon formation of the complex. We observed similar, albeit less
255 pronounced effect also for the TgELC1-TgMyoA-C^{ELC} complex assembly (S3D Fig). We
256 anticipate that the increase in α -helical secondary structure content corresponds to the

257 induction of the structure of the TgMyoA C-terminus, which in turn stiffens the TgMyoA lever
258 arm and enhances the performance of TgMyoA in the full-length context.

259

260 **TgELC1 and TgELC2 form structurally similar complexes with MyoA and MLC1**

261 To gain detailed information on the architecture of the trimeric protein assemblies, we
262 crystallized and determined the crystal structures of the following trimeric complexes: *T. gondii*
263 MLC1/TgMyoA-C/TgELC1 complex at 2.4 Å resolution (hereafter named complex 1) and
264 *T. gondii* MLC1/TgMyoA-C/TgELC2 complex at 2.3 Å resolution (hereafter named complex 2)
265 (Fig 5A-B, Table 2). Overall, both complexes display a similar architecture. MyoA folds into an
266 extended α helix with a characteristic kink between residues 801-803 (angle of 139° in
267 complex 1 and 137° in complex 2). Both TgELCs display a typical calmodulin fold with one
268 N-terminal and one C-terminal lobe, each lobe comprised of two EF hands. With the exception
269 of the first EF hand, all EF hand sequences deviate from the canonical EF hand sequence
270 and as expected, do not bind any ions. However, clear additional electron density was visible
271 for the first EF hand and assigned to a bound calcium ion coordinated in a
272 tetragonal-bipyramidal geometry. Both TgELCs form conserved polar interactions with
273 TgMyoA, involving TgMyoA residues E787, R793, R794 and K796, a π - π stacking interaction
274 between the conserved residue pair W779-F79 and a group of hydrophobic residues clustered
275 around the conserved TgMyoA region P801-Y810 (Fig 5C-D, S4 Table). Mutational analysis
276 on TgELC2 (Table 3, S4A Fig) showed that disrupting one of the polar interactions or the
277 conserved π - π stacking interaction W779-F77 only has a minor effect on the binding affinity
278 of TgMyoA to TgELC2 and suggests that the hydrophobic residues in the conserved MyoA
279 region play a crucial role for complex formation. In general, TgELC1 forms tighter interactions
280 with TgMyoA-C than TgELC2, with a higher number of interatomic interactions and a larger
281 protein-protein interface (S4 table, Fig 5C-D), which is consistent with the difference in the
282 binding affinity of the dimeric complexes measured by ITC (Fig 3C-D, Table 3).

283 This tighter interaction is also reflected in the SAXS data measured for both trimeric complexes
284 where the extracted molecular weight estimates are consistent with the expected molecular
285 weights (Fig 5F, S2 Table). Complexes 1 and 2 are monomeric in solution but whereas the
286 calculated scattering data of complex 1 fit the experimental scattering data with a X^2 of 1.26,
287 the structure of complex 2 displays a higher $X^2 = 2.41$, suggesting some structural differences
288 in solution. In addition, the scattering data of the *P. falciparum* trimeric complex of MTIP,
289 PfELC and PfMyoA-C are very similar to the *T. gondii* homologues, suggesting that the overall
290 architecture of the complexes is conserved between *P. falciparum* and *T. gondii* (Fig 5F,
291 S2 Table).

292 To investigate whether MLC1 binding to the preformed dimeric complex induces additional
293 conformational changes in TgELC2, we recorded SAXS data of the TgELC2-TgMyoA-C^{ELC}
294 dimeric complex (Fig 5E). The resulting scattering data are in excellent agreement with the
295 calculated scattering profile from the trimeric complex omitting MLC1 (X^2 of 1.16 Å) indicating
296 no major structural rearrangements. Similarly, MLC1 adopts the same conformation as in the
297 already described structure of a MLC1-MyoA⁸⁰³⁻⁸³⁰ dimeric complex (PDB ID 5vt9), with a
298 backbone RMSD of 0.96 Å compared to complex 1 and 0.75 Å compared to complex 2
299 (S4B-C Fig). The key interactions of TgMyoA with MLC1 are also conserved between the
300 structures of the trimeric and dimeric complexes (R808, H812, R814) with the exception of
301 few weak polar interactions (see S4 Table).

302 In general, the N-termini of MLC1 and its *P. falciparum* homolog MTIP were shown to anchor
303 myosin A to the inner membrane complex by interacting with GAP45 *in vivo* [31]. Interestingly,
304 although the same construct of MLC1 was used for crystallization in all cases (residues
305 66-210), the quality of the electron density only allowed to build the N-terminal part of the
306 model to different extents in complex 1 (from residue 77), complex 2 (from residue 67) and
307 the previously solved structure of the dimeric complex of MLC1 and TgMyoA C-terminus (from
308 residues 73, 5vt9, [15]). These differences indicate that the N-terminal residues of MLC1⁶⁶⁻²¹⁰
309 in solution show a certain degree of disorder. To further investigate the structure of the
310 N-terminal residues of MLC1 in solution, we recorded SAXS data of complex 1 with full-length

311 MLC1 (residues 1-213) and two MLC1 constructs with a truncated N-terminus (MLC1⁶⁶⁻²¹⁰,
312 which was also used for crystallization, and MLC1⁷⁷⁻²¹⁰; Fig 5F-G, S4D Fig).

313 The complex containing full-length MLC1 displays a significantly higher maximum particle size
314 (D_{\max} =14 nm) and a larger radius of gyration (3.50 ± 0.02 nm) in comparison to the complex
315 used for crystallization (S2 Table), suggesting that the MLC1 N-terminus is disordered in the
316 complex with TgMyoA and TgELC1. The D_{\max} decreases even further from 9.5 nm to 8.2 nm
317 upon truncating the MLC1 construct by additional eleven residues (from MLC1⁶⁶⁻²¹⁰ to
318 MLC1⁷⁷⁻²¹⁰). However, the eleven N-terminal residues (66-76) of MLC1 in complex 2 form an
319 α helix that folds back towards the center of the molecule and therefore does not effectively
320 increase the maximum particle size of the molecule. The difference in the measured particle
321 size thus indicates that the structural elements upstream of residue 77 of MLC1 are flexible in
322 solution (Fig 5G). Moreover, the SAXS data of complex 1 with the shortest MLC1 construct
323 (77-210) agree well with the calculated scattering profile of the crystal structure ($X^2=1.04$),
324 whereas the fit of the complex with MLC1⁶⁶⁻²¹⁰ is slightly poorer ($X^2=1.26$), further supporting
325 that residues 66-76, which could not be resolved in all crystal structures, are at least partially
326 disordered. The flexibility within residues 66-76 is additionally apparent from the normal mode
327 analysis (S6A Fig, see below). Thus, MLC1 residues 77-213 form a rigid complex with the
328 C-terminus of TgMyoA, whereas residues 1-76 are flexible. This feature may have further
329 implications on the function of the protein, namely anchoring MyoA to the membranes of the
330 IMC or interacting with other members of glideosome, such as GAP45.

331

332 **Calcium stabilizes the trimeric complexes by mediating ELC interactions to MLC1**

333 Apicomplexan invasion is a tightly regulated process, which also involves an increase in
334 intracellular calcium concentration. To investigate the role of calcium bound in the first EF
335 hand of both TgELCs, we determined an additional crystal structure of the calcium-free
336 complex TgELC1/MLC1/MyoA-C at 2.0 Å (complex 1f, Fig 6A, Table 2). The calcium-free
337 complex generally adopts the same conformation as complex 1. The MyoA-C helix is kinked

338 at a similar angle (134°), and the binding interfaces between MLC1 and TgMyoA as well as
339 between TgELC1 and MyoA are identical to complex 1 (S4 Table). The calcium binding
340 residues remain in the same conformation as in complex 1 except for side chain of
341 aspartate 17 which is flipped by 120 degrees and thereby enables the release of calcium from
342 the binding pocket (Fig 6B). In complex 1, calcium is coordinated in a tetragonal bipyramidal
343 geometry by the carboxyl groups of side chains D15, D17, D19, the carbonyl group of E21
344 and two water molecules. In complex 2, calcium is similarly coordinated by the homologous
345 side chain residues of D16, N18, D20, the carbonyl group of E22 and two water molecules.
346 Additionally, in complex 2, these water molecules are further stabilized by interactions with the
347 side chains of E27 and Q49. Contrary to the *T. gondii* TgELCs, the homologous EF hand loop
348 of PfELC is bent to the other side and does not possess the residues needed for coordination
349 of calcium (Fig 6B). In agreement with the presented crystal structures, calcium has no major
350 influence on the secondary structure of individual TgELCs or PfELC in solution (S5A-C Fig).
351 Powell et al. recently showed that the absence of calcium reduces the affinity of TgELC1 for
352 the MyoA C-terminus [15]. To investigate this effect in TgELC2, we mutated the crucial calcium
353 binding residue D16 in the first EF hand to alanine. As expected, the complex of
354 TgELC2^{D16A}/MyoA-C^{ELC} could not be stabilized against heat unfolding by the addition of
355 calcium (Fig 6C). However, the complex of TgELC2^{D16A}/MyoA-C^{ELC} was also less stable
356 compared to the wild type complex independent of the bound calcium and the effect of the
357 mutation on the affinity of the dimeric complex was negligible (Table 3 and S5B Fig).
358 Based on the available crystal structure we speculated that calcium ions might be crucial to
359 form an interaction surface between the EF hand of TgELCs and MLC1. The structures of the
360 trimeric complexes show several polar interactions in this interface (6D-F Fig, S4 Table).
361 Therefore, we mutated selected TgELC2 or MLC1 residues at this interface to alanine and
362 measured the binding affinity for trimeric complex formation. The observed decrease in affinity
363 was only moderate (up to five-fold) but the measured affinities reached the limitations of
364 reliable high affinity ITC measurements (Table 3 and S5C Fig). Therefore, we turned to
365 stability measurements and observed a pronounced concentration dependent effect of

366 calcium ions on the thermal stability of the entire complex in a concentration dependent
367 manner (Fig 6G-H, S5D Fig). In conclusion, calcium binding by the first EF hand of TgELCs
368 does not impact the formation of the complex but contributes substantially to the stability of
369 the complex by maintaining the interface between MLC1 and TgELCs.

370 **Trimeric complexes with full-length myosin A resemble the dynamics of conventional** 371 **myosins in the pre-power stroke state**

372 Previously solved structures of myosins in complex with their light chains suggest that the
373 converter domains interact with the essential light chain to further stabilize the rigid lever arm
374 and possibly transmit the structural changes from the myosin motor domain to the lever arm
375 [32,33]. Similar to that, it has been proposed that TgELC1 might constitute a small binding
376 interface with the TgMyoA converter domain [15], providing enhanced rigidity to the myosin
377 lever arm. To investigate whether the crystal structures of complex 1 and complex 2 are
378 compatible with these observations and ensure that they do not clash with the TgMyoA core,
379 we built structural models of the TgMyoA motor and neck domain bound to MLC1 and TgELC1
380 or TgELC2. For model building, we made use of the crystal structure of the TgMyoA motor
381 domain in the pre-power stroke state (PDB ID 6due [23], residues 33-771) and extended its
382 C-terminus by an α helix (TgMyoA residues 772-791), which resulted in 50 MyoA models.
383 Subsequently, the MyoA residues 780-791 of the crystal structures of complex 1 or complex
384 2 were aligned to these models and five models of each complex with the lowest clash score
385 were energy minimized. The details of model building are described in the Methods section.
386 In all cases, the energy-minimized models did not contain any clashes, indicating that our
387 structures are compatible within the full-length context of TgMyoA (Fig 7A-B). TgMyoA
388 residues 762-818 constituting the lever arm maintained a continuous α helix after energy
389 minimization with both TgELC1 and TgELC2 forming a small number of contacts with the
390 TgMyoA converter domain. These contacts mainly involve the side chain of arginine 81 of
391 TgELC1 or TgELC2 and residues 720-724 of TgMyoA, which is in agreement with the
392 previously published HDX data [15]. To further explore the dynamics of full-length TgMyoA

393 with its light chains, we performed normal mode analysis in an all-atom representation on five
394 energy-minimized models from each complex 1 and complex 2, and subsequent deformation
395 analysis which allowed us to identify potential hinge regions within these structures. In both
396 cases, all five reconstructed models displayed nearly identical pattern of motions (see S6A
397 Fig for complex 2): the structures undergo bending in the hinge region of TgMyoA residues
398 773-777 in two perpendicular directions (mode 7 and 8) as well as twisting in the same region
399 (mode 9). In the remaining modes (modes 9 and higher), the movement further propagates
400 throughout the lever arm helix up to TgMyoA residue 799. As a result, the deformation analysis
401 of the 20 lowest energy modes predicted the hinge region of the TgMyoA lever arm between
402 TgELCs and the converter domain, and an additional hinge between TgELCs and MLC1
403 (complex 2 in Fig 7C and complex 1 in S6B Fig). Such dynamics of the myosin light chains is
404 similar as previously described in conventional myosins [33,34] and the flexibility in the first
405 TgMyoA hinge can contribute to the efficient rebinding of the myosin motor domain to actin in
406 the pre-power stroke state (6SC Fig) [35]. In conclusion, the structures of the trimeric
407 complexes composed of the TgMyoA light chains and TgMyoA C-terminus are compatible with
408 the full-length TgMyoA and exhibit dynamics that is similar to the dynamics of conventional
409 myosins.

410 **Discussion**

411 The gliding motility of apicomplexan parasites is generated by a myosin-A-based molecular
412 motor that is anchored in the inner apicomplexan membranes by a multi-protein complex
413 called the glideosome. While the structures of some individual glideosome components and
414 small dimeric complexes have been solved for *T. gondii* and *P. falciparum* so far, they do not
415 explain their roles in the glideosome assembly and regulation. In this study, we present
416 structures of trimeric glideosome complexes consisting of the TgMyoA C-terminus, MLC1 and
417 TgELC1 or TgELC2 and investigate the role of essential light chains in glideosome assembly
418 and function.

419 **Binding of essential light chains and induced folding**

420 We showed that the α -helical content of *P. falciparum* PfELC is lower compared to *T. gondii*
421 ELCs and that the C-terminus of PfELC in isolation is disordered. However, the α -helical
422 secondary structure content of *T. gondii* ELCs is even higher in the above described crystal
423 structures of the trimeric complexes compared to the percentages calculated from the CD
424 measurements on proteins in isolation. We assume that the C-termini of PfELC as well as
425 TgELCs are partially disordered, although to a different degree, and constitute the typical
426 calmodulin fold only upon binding to the MyoA neck domain. This seems plausible because
427 no structure of essential light chain has been solved in isolation so far and it has been
428 suggested that they are disordered in the unbound state [36].

429 The main role of essential light chains is to support the structure of the myosin neck which,
430 together with the light chains and myosin converter domain, serves as myosin lever arm
431 [27,36–38]. Contrary to previously published results [14], we were able to show that ELCs bind
432 to the same conserved region of MyoA and therefore we expect the structure of PfELC bound
433 to PfMyoA to be similar to the *T. gondii* structures presented here. We could show that the
434 C-terminus of myosin A is disordered (TgMyoA) or only partially ordered (PfMyoA), whereas
435 in the trimeric complexes, TgMyoA forms a continuous α helix. Therefore, we propose that the
436 binding of essential light chains and their respective myosin binding sites mutually induces

437 folding of both components and thereby stiffens the myosin lever arm. In turn, the myosins are
438 capable of undergoing a larger step size and thus increase their speed, which is in agreement
439 with the previous measurements of both *T. gondii* and *P. falciparum* myosin A motors
440 [14,16,17].

441 **Implications on myosin A regulation**

442 In general, the myosin light chains together with the myosin heavy chain neck region constitute
443 a regulatory domain, which influences the biochemical and mechanical properties of myosins
444 either upon phosphorylation [39–42] or by direct binding of calcium [43,44]. Indeed,
445 apicomplexan invasion is accompanied by an increase of intracellular calcium concentration
446 and activation of several kinases [45–47]. The apicomplexan MLC1 or MTIP do not contain
447 the N-terminal signature sequence (RxxS) necessary for the recognition by myosin light chain
448 kinases as in muscle myosins [48] and therefore must follow different regulatory pathways. It
449 has been shown that phosphorylation of TgMyoA S21 and S743 [49] and PfMyoA S19 [24]
450 upregulates the myosin motor. On the other hand, *P. falciparum* MTIP phosphorylation at S108
451 impairs the affinity of MTIP to PfMyoA by increased electrostatic repulsion from the adjacent
452 MTIP residue E179 [22]. The previously identified phosphorylation sites of MLC1 (S55, T98,
453 S132) [47] are not homologous to MTIP phosphorylation sites (S47, S51, S85/86, S108)
454 [22,46] and all of them locate to the N-terminal disordered domain or distant from the binding
455 interface with ELCs and MyoA, making them unlikely to be directly involved in myosin motor
456 regulation. The structure of the glideosome trimeric complex 2 revealed another possible site
457 of the myosin A regulation at TgELC2 residue S102, which has been previously shown to be
458 phosphorylated in *T. gondii* tachyzoites [50]. In the trimeric complex, S102 forms a hydrogen
459 bond with TgMyoA E787 and we expect that an additional negative charge would have a
460 repulsive effect and decrease the binding affinity of TgELC2. Interestingly, residue S102 is not
461 conserved in TgELC1 and could explain the presence of two essential light chains in *T. gondii*:
462 they might be used by the parasite in different life stages, where a different type of myosin
463 regulation is required. In addition, it cannot be excluded that the essential light chains are

464 promiscuous and might be able to bind to other myosins, too. Although both *T. gondii* essential
465 light chains have been shown to interact with the glideosome *in vivo* [16], transcriptomic data
466 indicate a higher gene expression level of TgELC1 compared to TgELC2 throughout all life
467 stages except during oocyst development [51], suggesting that TgELC2 might play additional
468 roles in other cellular processes than invasion and motility.

469 Another mode of regulation described in classical myosins is calcium binding. Similarly, to
470 other essential light chains, TgELC1 and TgELC2 bind calcium in their first EF hand by
471 residues just adjacent to the interface with MLC1. The calcium ion is supposed to support the
472 stiffness of the myosin helix kink (TgMyoA residues 801-803) and mediate transfer of the small
473 conformational changes of the distal regulatory light chain upon phosphorylation to the myosin
474 motor domain [35,43]. Contrary to that, the calcium-free crystal structure of complex 1
475 displayed an identical conformation, forming an even larger interface with MLC1 than the
476 calcium-bound structure. Moreover, the normal mode analysis has shown that conformational
477 flexibility of the helical hinge of TgMyoA (residues 801-803) is limited and further propagates
478 downstream of residues 799 with a main deformation hinge in the TgMyoA helical hinge
479 between residues 773-777. This suggests that calcium does not play a role in myosin A
480 regulation but rather stabilizes the complex *per se*. Such conclusion is also supported by
481 previously published functional data, which show that the absence of calcium does not alter
482 the function of the myosin A motor in neither *P. falciparum* [17] nor *T. gondii* [13].

483 **Assembly of the glideosome**

484 Finally, essential light chains generally interact with the myosin converter domain and
485 presumably stabilize the hinge of the myosin neck between the ELC and the converter domain
486 (TgMyoA residues 775-777) [34,35]. A small interaction interface between the converter
487 domain and TgELC1 has also been shown previously [15]. Our models now show that both
488 TgELC1 and TgELC2 form few polar interactions with the converter domain, however, these
489 are not sufficient to maintain the rigid structure and the TgMyoA hinge between ELC and the
490 converter domain contributes to most of the movement of the myosin complex. Nevertheless,

491 the normal mode analysis was performed in the absence of a bound nucleotide and the
492 interface between TgELCs and the converter domain might become more rigid once TgMyoA
493 binds ATP, as previously described for other myosins [52].

494 It still remains elusive how myosin A and its light chains attach to the inner membrane complex
495 and bind the glideosome associated proteins. Although MLC1/MTIP are lipidated at their
496 N-terminus, they have been shown to form a pre-complex with GAP45 which is indispensable
497 for correct MyoA location [10]. Given the disordered nature of the MLC1/MTIP N-termini and
498 GAP45 in isolation [53], we propose that the proteins interact and mutually induce their
499 secondary structure upon binding, similarly to the ELC-MyoA interaction described here. We
500 expect that this interaction can be fine-tuned by phosphorylation of both MLC1/MTIP and
501 GAP45. Moreover, as both GAP45 and MLC1/MTIP are lipidated and on the other hand, the
502 transmembrane regions of both GAP40 and GAP50 are highly conserved, we propose that
503 GAP40 or GAP50 directly bind the lipidation moieties of GAP45 and/or MLC1/MTIP to
504 immobilize the glideosome in the 2D plane of the inner membrane complex.

505 In conclusion, our study extends the knowledge on the structure and mechanism of the
506 glideosome. Partially disordered ELCs stiffen the MyoA lever arm by mutual induction of
507 structure upon binding and together with MLC1/MTIP form complexes that are structurally
508 conserved between *T. gondii* and *P. falciparum*. The structures revealed that calcium is not
509 directly involved in the myosin motor regulation, but uncovered an additional potential site of
510 regulation by phosphorylation in TgELC2. Nonetheless, the complete understanding of the
511 molecular basis of apicomplexan motility and invasion will require further research and it will
512 be interesting to unravel how the glideosome anchors to other proteins of the IMC and how
513 the parasites regulate the action of differently localized myosins on a temporal scale.

514 **Materials and methods**

515 **Cloning**

516 Open reading frames encoding TgELC2 (TGME49_305050) and TgMLC1 (TGME49_257680)
517 subcloned *via* NdeI/XhoI restriction enzymes into pET28a(+)-TEV vector were purchased from
518 *GenScript*. The TgELC1 gene was cloned by extending the TGME49_269442 open reading
519 frame (*GenScript*) and cloning into a pNIC28_Bsa4 [54] vector *via* BsaI restriction sites. DNA
520 sequences of PfELC (PF3D7_1017500), PfELC-N (residues 1-74), PfMTIP (PF3D7_1246400)
521 and PfMTIP-S (residues 60-204) were amplified from *P. falciparum* 3D7 cDNA and cloned into
522 a pNIC28_Bsa4 vector *via* BsaI restriction sites. These constructs have an N-terminal
523 TEV-cleavable His₆-tag. TgMLC1-S (residues 66-146) was subcloned into a pNIC_CTHF [54]
524 vector *via* the BfuI restriction site. The vector has a C-terminal TEV-cleavable His₆-tag and
525 FLAG-tag. The sequence encoding TgMyoA-C was amplified by two complementary primers
526 and cloned *via* NcoI/KpnI restriction enzymes into a pET_GB1 vector. This construct contains
527 an N-terminal TEV-cleavable His-GB1 domain. Expression cassettes of His-TgELC1 and His-
528 GB1-TgMyoA-C were then subcloned *via* NdeI/XbaI restriction enzymes into a pPYC [55]
529 vector. The His-GB1-TgMyoA-C gene was then cut by SpeI/XbaI restriction enzymes and
530 inserted into SpeI-cut pPYC-His_TgELC1 to construct the co-expression vector pPYC with
531 TgELC1 and TgMyoA-C.

532 **Mutagenesis**

533 Site directed mutants were generated by blunt-end PCR. Briefly, the plasmids were amplified
534 by primers which contain the alternative bases on their 5' ends and anneal upstream and
535 downstream of the target triplet. The PCR products were digested by DpnI (NEB) overnight at
536 37 °C and purified by a PCR purification kit (Qiagen). Subsequently, the 5' ends of the PCR
537 products were phosphorylated by T4 polynucleotide kinase (NEB), the products were purified
538 and the free ends of the plasmid re-ligated by T4 DNA ligase (NEB). The positive clones were
539 subsequently selected and their sequence was verified by sequencing.

540 **Protein expression and purification**

541 The proteins were overexpressed in *E. coli* BL21(DE3) (MLC1, MTIP, MTIP-S, co-expressed
542 TgELC1-TgMyoA-C + MLC1-S) or *E. coli* BL21-CodonPlus(DE3)-RIL (TgELC1, TgELC2,
543 PfELC, PfELC-N, MLC1-S), in TB medium. The bacterial cultures were induced at OD_{600nm} of
544 0.6 with 1 mM IPTG and harvested after 4 hours at 37 °C (TgELC1, TgELC2, PfMTIP) or
545 induced at OD_{600nm} of 0.6 by 0.2 mM IPTG and harvested after 16 hours at 18 °C (PfELC,
546 PfELC-N, MLC1). The expression of PfELC and PfELC-N for NMR measurements was
547 performed in minimal expression medium as described elsewhere [56].

548 The cell pellets were resuspended in lysis buffer (20 mM NaP (pH 7.5), 300 mM NaCl, 5%
549 glycerol, 15 mM imidazole, 5 units/ml DNase I, 1 tablet of protease inhibitors (*Roche*) per
550 100 mL buffer, 1 mg/mL lysozyme, 0.5 mM TCEP) and the bacteria were lysed by three
551 passages through an emulsifier (EmulsiFlex-C3, Avestin) with a maximum pressure of
552 10 000 psi. The lysate was centrifuged (20 min, 19 000g) and incubated with 2 ml of Ni-IMAC
553 beads (ThermoFisher) per 1 l of culture on a rotatory wheel (1 h, 4 RPM). The lysate was then
554 transferred into a gravity column and washed twice with 10 ml wash buffer (20 mM NaP (pH
555 7.5), 300 mM NaCl, 5% glycerol, 15 mM imidazole, 0.5 mM TCEP). The bound protein was
556 eluted with 10 ml and subsequently with 5 ml of elution buffer (20 mM NaP (pH 7.5), 150 mM
557 NaCl, 5% glycerol, 250 mM imidazole, 0.5 mM TCEP). The elution fractions were pooled and
558 0.5 mg of TEV protease per liter of bacterial culture was added. The samples were dialyzed
559 (2 kDa cut-off) against 500 ml wash buffer or, in case of PfELC and PfELC-N, against 50 mM
560 Tris (pH 8.0), 20 mM NaCl, 0.5 mM TCEP overnight. Next day, the samples were incubated
561 on a gravity column with 1 ml Ni-beads per 1 l of culture. The flow-through was concentrated
562 (10 kDa cut-off) to maximum of 10 mg/ml and further purified by size exclusion
563 chromatography on a Superdex 200 HiLoad column (GE Healthcare; PfELC, MTIP, MTIP-S,
564 MLC1, MLC1-S) or on a Superdex 75 HiLoad column (GE Healthcare; TgELC1, TgELC2,
565 PfELC-N, co-expressed TgELC1-TgMyoA-C), using gel filtration buffer (20 mM HEPES
566 (pH 7.5), 150 mM NaCl, 0.5 mM TCEP). Finally, the samples were concentrated
567 (10 kDa cut-off) up to 15 mg/ml and either directly used or flash-frozen for later use. Due to

568 instability, PfELC was always directly used within 3 days of the purification without freezing.

569 All steps were performed at 4 °C.

570 **SDS-PAGE analysis**

571 The concentrated samples of PfELC were dialyzed against 50 mM Tris (pH 8.0), 20 mM NaCl,
572 and 0, 0.25, 0.5 or 1 mM TCEP overnight at 4 °C. Subsequently, the protein concentration
573 was adjusted to 1 mg/ml and 50 µl of each sample was mixed with a fivefold excess of
574 2-iodoacetamide. The samples were incubated for 1 h at 37 °C and afterwards, 10 µl of each
575 sample was mixed with 5 µl of non-reducing loading dye. The gel was run at 180 V for 40 min
576 and stained by Direct Blue.

577 **Analytical gel filtration**

578 The proteins and protein complexes were analyzed by analytical gel filtration using a
579 Superdex 200 5/150 column (GE Healthcare) and the 1260 Infinity Bio-inert high-performance
580 liquid chromatography system (Agilent Technologies) at 10 °C. The system and column were
581 equilibrated in 20 mM HEPES (pH 7.5), 150 mM NaCl, 0.5mM TCEP and 30 µl of each sample
582 was injected by an autosampler. The system was run at 0.2 ml/min for 20 minutes and the
583 elution profile was recorded by a UV detector.

584 **Thermal shift assay**

585 The stability of the different proteins was measured by nanoDSF (Prometheus NT.48,
586 NanoTemper Technologies, GmbH). The proteins were first dialyzed against 1 l of gel filtration
587 buffer supplemented with 5 mM EDTA overnight at 4 °C and subsequently 2x against 1 l of
588 gel filtration buffer without EDTA overnight at 4 °C. The protein concentration was then
589 adjusted to 100 µM (individually or 100 µM each component of a complex) in gel filtration
590 buffer and varying concentration of calcium chloride (0 – 500 µM). 10 µl of samples was
591 loaded in the glass capillaries and heated from 20 °C to 95 °C with a heating rate of 1 °C/min.
592 The fluorescence signals with excitation wavelength of 280 nm and emission wavelengths of
593 330 and 350 nm were recorded and the melting temperature was calculated as either

594 maximum of the derivative of ratio of fluorescence at 330 and 350 nm, or as maximum of the
595 derivative of the fluorescence at 330 nm.

596 **Circular dichroism**

597 To estimate the secondary structure content of the proteins and peptides, we measured
598 circular dichroism on a Chirascan CD spectrometer (Applied Photophysics). For spectrum
599 measurements, the protein or peptide concentration was adjusted to 100 μ M and diluted
600 tenfold by 10 mM NaP (pH 7.5), 20 mM NaCl, 0.25 mM TCEP just prior to the measurement.
601 To measure the difference in secondary structure content in presence or absence of calcium,
602 the proteins were first dialyzed against 1 l of gel filtration buffer supplemented with
603 5 mM EDTA overnight at 4 °C and subsequently 2x against 1 l of gel filtration buffer
604 supplemented with \pm 1 mM CaCl_2 overnight at 4 °C. The proteins were then diluted to 5 μ M or
605 10 μ M with 10 mM NaP (pH 7.5), 20 mM NaCl, 0.25 mM TCEP and \pm 1 mM CaCl_2 just prior to
606 the measurement. The CD spectrum was measured between 200 nm and 260 nm with 1 nm
607 steps in triplicates using a 2 mm quartz cuvette. To assess the induction of structure in the
608 dimeric protein complexes, each component was diluted by 10 mM NaP (pH 7.5), 150 mM
609 NaF and 0.25 mM TCEP to a final concentration of 5 μ M. The circular dichroism was
610 measured 10x between 195 nm and 260 nm with 0.5 nm step in 1 mm quartz cuvette. The
611 data were averaged, background subtracted and analyzed by K2D algorithm [57] using
612 DichroWeb [58].

613 **Isothermal titration calorimetry**

614 To measure the interaction of TgELC1 or TgELC2 and its mutants with the TgMyoA-C^{ELC}
615 peptide (S777-Q798), the peptides were dissolved and the proteins were dialyzed in gel
616 filtration buffer, overnight at 4 °C and 2 μ l of a 200 μ M peptide solution were injected 19 times
617 into 20 μ M protein. To measure the interaction of the trimeric complex, first, the peptides were
618 dissolved and the proteins dialyzed against gel filtration buffer supplemented with 1 mM CaCl_2 .
619 The complex of TgELC1, TgELC2 or MTIP-S with the MyoA peptide (S777-V818 in *T. gondii*,
620 V775-V816 in *P. falciparum*) was first formed in 1:1.1 molar ratio, respectively, and incubated

621 for 1 h at 4 °C. For measurement, 2 µl of 200 µM TgMLC-S or PfELC was injected 19 times
622 into 20 µM of the pre-formed complex. The measurements were performed with a
623 MicroCal PEAQ-ITC (Malvern) at 25 °C. The data were processed using the
624 MicroCal PEAQ-ITC Analysis Software and fitted with a one-site binding model.

625 **Bioinformatics methods**

626 The homologous protein sequences were aligned with the program MAFFT [59]. The protein
627 disorder probability was calculated using the disEMBL [60] server with loops and coils defined
628 by dictionary of secondary structure of proteins [61]. The secondary structure prediction of
629 PfELC, TgELC1 and TgELC2 was calculated in JPred [62].

630 **Small angle X-ray scattering**

631 The SAXS data were collected at the P12 BioSAXS beamline [63] at the PETRA III storage
632 ring (DESY, Hamburg, Germany). The concentrated samples of TgELC2 and PfELC
633 (10 mg/ml) were dialyzed against the buffer (20 mM HEPES (pH 7.5), 150 mM NaCl,
634 0.5 mM TCEP for TgELC2; 20 mM Tris (pH 8.0), 150 mM NaCl, 0.5 mM TCEP for PfELC-N)
635 overnight at 4 °C. Further, the samples were centrifuged (5 min, 15 000g, 4 °C) and a dilution
636 series of each sample (typically in a range of 0.5 – 10 mg/ml) and their corresponding solvent
637 were measured at room temperature under continuous flow with a total exposure of 1 s
638 (20 x 50 ms frames). The dimeric complex TgELC2/TgMyoA-C, as well as the trimeric
639 complexes using different constructs, were mixed in 1:1 or 1:1:1 molar ratio, purified by SEC
640 and concentrated to 10 mg/ml prior to the measurement. The X-ray scattering data were
641 measured in an on-line SEC-SAXS mode, using a SD200 Increase column (GE Healthcare)
642 at 0.5 ml/min with 1 frame recorded per second. The sample of PfELC was concentrated to
643 10 mg/ml and the X-ray scattering was measured in the on-line SEC-SAXS mode, using a
644 SD200 5/150 column at 0.4 ml/min. The automatically processed data were further analyzed
645 using the ATSAS suite [64] programs CHROMIXS [65] and PRIMUS [66] to determine the
646 overall parameters and distance distribution, CRY SOL [67] to compute the scattering from the

647 crystal structures and CORAL [68] to compute the scattering from the crystal structures with
648 dummy residues mimicking the missing flexible parts.

649 **NMR**

650 All NMR experiments were conducted on a Bruker Avance II 800 NMR spectrometer equipped
651 with a cryoprobe at 288 °K in 50 mM HEPES, 20 mM NaCl, 0.5 mM TCEP and 10% (v/v) D₂O
652 at pH 7.0, except for H(CCO)NH-TOCSY and (H)C(CO)NH-TOCSY experiments that were
653 performed on a Bruker Avance III 600 NMR spectrometer equipped with a room temperature
654 probe. Full-length PfELC (residues 1-134) was ¹⁵N and ¹⁵N¹³C labeled and concentrated to
655 500 μM. PfELC-N was also ¹⁵N and ¹⁵N¹³C labeled and in addition site-selectively ¹³C labeled
656 [69–71] by using 1-¹³C₁ and 2-¹³C₁ glucose. Samples were concentrated to about 1 mM. All
657 spectra were processed using NMRPipe [72] and analyzed using NMRView [73].

658 Backbone resonances of ¹⁵N¹³C labeled samples (1-74 and 1-134) were assigned using
659 HNCACB [74] and HN(CO)CACB [75] experiments. Aliphatic side chains (1-74) were assigned
660 using H(CCO)NH-TOCSY [76] (H)C(CO)NH-TOCSY and H(C)CH-TOCSY [77] experiments.
661 Aromatic side chains (1-74) were assigned by (HB)CB(CGCD)HD [78] and aromatic H(C)CH-
662 TOCSY experiments and verified by the site-selective ¹³C labeling.

663 NOEs for the structure determination were derived from 3D-NOESY-HSQC experiments for
664 ¹⁵N, ¹³C aliphatic nuclei and ¹³C aromatic nuclei (on 1-¹³C₁ and 2-¹³C₁ glucose labeled
665 samples). Phi-Psi dihedral angle constraints were derived using TALOS [79]. Structure
666 calculations were performed using ARIA 2.3 [80] and standard parameters. The lowest-energy
667 models have been deposited in the PDB with accession number 6tj3.

668 {¹H}-¹⁵N NOE saturation was performed using a train of shaped 180° pulses in a symmetric
669 fashion [81–83] for 3 s and a total inter-scan relaxation period of 10 s. Data collection,
670 processing and analysis details are summarized in S3 Table.

671 **Crystallization**

672 PfELC-N was concentrated (5kDa cut-off) to 26 mg/ml and 200 nl of the sample was mixed
673 with 100 nl of reservoir solution (0.1M Tris-HCl (pH 8.5), 0.2M Li₂SO₄, 30% PEG 4000). The
674 crystals grew in sitting drop plates at 19 °C for 7 days.

675 The trimeric complex of MLC1-S, TgELC2 and TgMyoA-C (S777-V818) was mixed in a molar
676 ratio of 1.1: 1.1: 1, respectively. After 1 h of incubation, the trimeric complex was separated
677 by gel filtration in 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP using a Superdex 75
678 16/600 column (GE Healthcare). The fractions containing the peak of the trimeric complex
679 were concentrated (5 kDa cut-off) to 10 mg/ml. The crystals grew for 7 days at 19 °C in sitting
680 drop plates prepared by mixing 200 nl of the sample with 100 nl of reservoir solution (0.1 M
681 imidazole, 0.1 M MES monohydrate pH 6.5, 20% v/v PEG 500 MME, 10% w/v PEG 20 000,
682 0.12 M 1,6-hexadiol, 0.12 M 1-butanol, 0.12 M 1,2-propanediol, 0.12 M 2-propanol,
683 0.12 M 1,4-butanediol, 0.12 M 1,3-propanediol).

684 The recombinantly expressed dimeric complex of TgELC1 and TgMyoA-C (S777-V818) was
685 mixed with MLC1 in 1:1.1 molar ratio, incubated for 1 h and the trimeric complex was
686 separated by gel filtration in 20 mM HEPES pH 7.5, 150 mM NaCl, 0.5 mM TCEP using a
687 Superdex 75 16/600 column (GE Healthcare). The fractions containing the peak of the trimeric
688 complex were concentrated (5 kDa cut-off) to 10 mg/ml. The crystals of calcium-bound
689 complex grew 7 days at 19 °C in a sitting drop plates prepared by mixing 200 nl of the sample
690 with 100 nl of reservoir solution (20% w/v ethylene glycol, 10% w/v PEG 8000, 0.1M Tris
691 (base), 0.1M bicine pH 8.5, 0.09 M sodium nitrate, 0.09 M sodium phosphate dibasic, 0.09 M
692 ammonium sulfate). The crystals of calcium-free complex grew 7 days at 19 °C in a sitting
693 drop plate prepared by mixing 200 nl of the sample with 100 nl of reservoir solution (32% w/v
694 PEG 8000, 0.1M Tris pH 7.0, 0.2M LiCl).

695 **Data collection and structure determination**

696 The diffraction data of the trimeric complexes were collected at the P13 EMBL beamline of the
697 PETRA III storage ring (c/o DESY, Hamburg, Germany) at 0.966 Å wavelength and 100 °K
698 temperature using a Pilatus 6 M detector (DECTRIS). The diffraction data of PfELC-N were

699 collected at the P14 EMBL beamline of the PETRA III storage ring (c/o DESY, Hamburg,
700 Germany) at 0.966 Å and 100 °K temperature using an EIGER 16 M detector (DECTRIS). The
701 diffraction data were processed using XDS [84], merged with Aimless [85] and the phases
702 were obtained by molecular replacement with Phaser [86], using the structure of
703 peptide-bound TgMLC1 (PDB ID 5vt9) as a search model in case of the trimeric complexes
704 and NMR structure as search model in case of PfELC-N. In all cases, the models were further
705 built and refined in several cycles using PHENIX [88], Refmac [89] and Coot [90]. Data
706 collection and refinement statistics are summed up in the Table 2. PyMOL was used to
707 generate the figures, measure the angle of the helical kink, inter-molecular angles, distances
708 and RMSDs. PDBePISA [91] was used to characterize the intermolecular interfaces. The
709 atomic coordinates and the structure factors have been deposited in the PDB with accession
710 numbers 6tj4, 6tj5, 6tj6 and 6tj7.

711 **Modelling**

712 The modelling procedure was performed in Modeller version 9.18 [92]. We built 50 models for
713 the TgMyoA residues 772-791. These 50 models were fused to the structure of TgMyoA
714 (PDB ID 6due; residues 33-771). All 50 models were tilting along the bond/dihedral angle
715 between residue 771 and the first modelled residue, that is 772; at the same time, the residues
716 33-771 of the 6due structure remained fixed. Thus, each of the produced models consisted of
717 an intact crystal structure 6due (till residue 771) and *de novo* modelled fragment of 772-791.
718 Restraints in a form of i-i+4 h-bonding pattern were imposed in order to ensure that all 50
719 models have an α -helical conformation along the whole length of the *de novo* modelled
720 fragment, and also at the junction between residues 771 and 772. The crystal structure of
721 complex 1 (PDB ID 6tj5) or complex 2 (PDB ID 6tj7) were superposed on the 50 models using
722 the TgMyoA residues 780-791. After superposition, the modelled conformation of this
723 fragment was removed from the merged structures, which produced models consisting of an
724 intact crystal structure of TgMyoA (PDB 6due), the modelled helix of TgMyoA (residues
725 772-779) and the intact crystal structure of the complex 1 (50 models) or complex 2

726 (50 models), starting from the TgMyoA residue 780 of these structures. Next, all reconstructed
727 complexes were screened against the existence of atomic clashes using the Chimera software
728 [93] and the best five models (both complex 1 and complex 2) were energy minimized by
729 executing 1000 steps of conjugate gradient energy minimization in the NAMD program [94].
730 All energy minimizations were performed in a water box with ions.

731 **Normal mode analysis.** Normal mode analysis (NMA) [95] was used to probe essential
732 dynamics of the reconstructed trimeric models. The NMA was performed in an all-atom
733 representation on the best five energy-minimized models using the BIO3D software [96]. The
734 deformation analysis was performed, using the first 20, 50 and 100 modes, and also on the
735 first 10 modes separately. This allowed us to not only identify possible hinge points within the
736 studied structures of trimeric complexes, but also to determine which hinges correspond to
737 which modes.

738 **Acknowledgments**

739 We thank the Sample Preparation and Characterization facility of EMBL Hamburg for support
740 with nanoDSF, ITC measurements and with protein crystallization. We acknowledge all group
741 members for continuous support and feedback on the project and during manuscript
742 preparation. We would like to thank the group of Thomas R. Schneider at EMBL Hamburg for
743 access to the EMBL beamlines P13 and P14 and Guillaume Pompidor and Grzegorz
744 Chojnowski for help with data processing and initial model building.

745 **References**

- 746 1. World Malaria Report 2018. 2018. Available:
747 <https://www.who.int/malaria/publications/world-malaria-report-2018/en/>
- 748 2. Dubey JP. Toxoplasmosis of animals and humans. 2nd ed. Beltsville, Maryland: CRC
749 Press; 2010. doi:10.1201/9781420092370
- 750 3. Cowman AF, Tonkin CJ, Tham WH, Duraisingh MT. The Molecular Basis of
751 Erythrocyte Invasion by Malaria Parasites. *Cell Host Microbe*. 2017;22: 232–245.
752 doi:10.1016/j.chom.2017.07.003
- 753 4. Frénal K, Dubremetz JF, Lebrun M, Soldati-Favre D. Gliding motility powers invasion
754 and egress in Apicomplexa. *Nature Reviews Microbiology*. 2017.
755 doi:10.1038/nrmicro.2017.86
- 756 5. Heintzelman MB. Gliding motility in apicomplexan parasites. *Seminars in Cell and
757 Developmental Biology*. 2015. doi:10.1016/j.semcd.2015.09.020
- 758 6. Kono M, Prusty D, Parkinson J, Gilberger TW. The apicomplexan inner membrane
759 complex. *Front Biosci*. 2013. doi:10.2741/4157
- 760 7. Gaskins E, Gilk S, DeVore N, Mann T, Ward G, Beckers C. Identification of the
761 membrane receptor of a class XIV myosin in *Toxoplasma gondii*. *J Cell Biol*.
762 2004;165: 383–393. doi:10.1083/jcb.200311137
- 763 8. Jones ML, Kitson EL, Rayner JC. *Plasmodium falciparum* erythrocyte invasion : A
764 conserved myosin associated complex. 2006;147: 74–84.
765 doi:10.1016/j.molbiopara.2006.01.009
- 766 9. Soldati-Favre D. Molecular dissection of host cell invasion by the Apicomplexans: the
767 glideosome. *Parasite*. 2008. doi:10.1051/parasite/2008153197
- 768 10. Frénal K, Polonais V, Marq JB, Stratmann R, Limenitakis J, Soldati-Favre D.
769 Functional dissection of the apicomplexan glideosome molecular architecture. *Cell
770 Host Microbe*. 2010. doi:10.1016/j.chom.2010.09.002
- 771 11. Dobrowolski JM, Carruthers VB, Sibley LD. Participation of myosin in gliding motility
772 and host cell invasion by *Toxoplasma gondii* . *Mol Microbiol*. 1997.
773 doi:10.1046/j.1365-2958.1997.5671913.x
- 774 12. Meissner M, Schlüter D, Soldati D. Role of *Toxoplasma gondii* myosin a in powering
775 parasite gliding and host cell invasion. *Science* 2002;298: 837–840.
776 doi:10.1126/science.1074553
- 777 13. Bookwalter CS, Kelsen A, Leung JM, Ward GE, Trybus KM. A *toxoplasma gondii*
778 class XIV myosin, expressed in Sf9 cells with a parasite co-chaperone, requires two
779 light chains for fast motility. *J Biol Chem*. 2014;289: 30832–30841.
780 doi:10.1074/jbc.M114.572453
- 781 14. Green JL, Wall RJ, Vahokoski J, Yusuf NA, Mohd Ridzuan MA, Stanway RR, et al.
782 Compositional and expression analyses of the glideosome during the *Plasmodium* life
783 cycle reveal an additional myosin light chain required for maximum motility. *J Biol
784 Chem*. 2017;292: 17857–17875. doi:10.1074/jbc.M117.802769
- 785 15. Powell CJ, Jenkins ML, Parker ML, Ramaswamy R, Kelsen A, Warshaw DM, et al.
786 Dissecting the molecular assembly of the *Toxoplasma gondii* MyoA motility complex.
787 *J Biol Chem*. 2017. doi:10.1074/jbc.M117.809632
- 788 16. Williams MJ, Alonso H, Enciso M, Egarter S, Sheiner L, Meissner M, et al. Two
789 essential light chains regulate the MyoA lever arm to promote *toxoplasma* gliding
790 motility. *MBio*. 2015;6: 1–16. doi:10.1128/mBio.00845-15
- 791 17. Bookwalter CS, Tay CL, McCrorie R, Previs MJ, Lu H, Kremmentsova EB, et al.
792 Reconstitution of the core of the malaria parasite glideosome with recombinant
793 *Plasmodium* class XIV myosin A and *Plasmodium* actin. *J Biol Chem*. 2017;292:
794 19290–19303. doi:10.1074/jbc.M117.813972
- 795 18. Rees-Channer RR, Martin SR, Green JL, Bowyer PW, Grainger M, Molloy JE, et al.

- 796 Dual acylation of the 45 kDa gliding-associated protein (GAP45) in *Plasmodium*
797 *falciparum* merozoites. *Mol Biochem Parasitol.* 2006;149: 113–116.
798 doi:10.1016/j.molbiopara.2006.04.008
- 799 19. Harding CR, Egarter S, Gow M, Jiménez-Ruiz E, Ferguson DJP, Meissner M. Gliding
800 Associated Proteins Play Essential Roles during the Formation of the Inner
801 Membrane Complex of *Toxoplasma gondii*. *PLoS Pathog.* 2016.
802 doi:10.1371/journal.ppat.1005403
- 803 20. Saini E, Zeeshan M, Brady D, Pandey R, Kaiser G, Koreny L, et al. Photosensitized
804 INA-Labelled protein 1 (PhIL1) is novel component of the inner membrane complex
805 and is required for *Plasmodium* parasite development. *Sci Rep.* 2017.
806 doi:10.1038/s41598-017-15781-z
- 807 21. Bosch J, Paige MH, Vaidya AB, Bergman LW, Hol WGJ. Crystal structure of GAP50,
808 the anchor of the invasion machinery in the inner membrane complex of *Plasmodium*
809 *falciparum*. *J Struct Biol.* 2012;178: 61–73. doi:10.1016/j.jsb.2012.02.009
- 810 22. Douse CH, Green JL, Salgado PS, Simpson PJ, Thomas JC, Langsley G, et al.
811 Regulation of the plasmodium motor complex: Phosphorylation of myosin a tail-
812 interacting protein (MTIP) loosens its grip on MyoA. *J Biol Chem.* 2012;287: 36968–
813 36977. doi:10.1074/jbc.M112.379842
- 814 23. Powell CJ, Ramaswamy R, Kelsen A, Hamelin DJ, Warshaw DM, Bosch J, et al.
815 Structural and mechanistic insights into the function of the unconventional class XIV
816 myosin MyoA from *Toxoplasma gondii*. *Proc Natl Acad Sci U S A.* 2018.
817 doi:10.1073/pnas.1811167115
- 818 24. Robert-Paganin J, Robblee JP, Auguin D, Blake TCA, Bookwalter CS, Kremmentsova
819 EB, et al. *Plasmodium* myosin A drives parasite invasion by an atypical force
820 generating mechanism. *Nat Commun.* 2019. doi:10.1038/s41467-019-11120-0
- 821 25. Dovega R, Tsutakawa S, Quistgaard EM, Anandapadamanaban M, Löw C, Nordlund
822 P. Structural and biochemical characterization of human PR70 in isolation and in
823 complex with the scaffolding subunit of protein phosphatase 2A. *PLoS One.* 2014.
824 doi:10.1371/journal.pone.0101846
- 825 26. Guinier A. La diffraction des rayons X aux très petits angles : application à l'étude de
826 phénomènes ultramicroscopiques. *Ann Phys (Paris).* 1939.
827 doi:10.1051/anphys/193911120161
- 828 27. Heissler SM, Sellers JR. Myosin light chains: Teaching old dogs new tricks.
829 *Bioarchitecture.* 2014. doi:10.1080/19490992.2015.1054092
- 830 28. Batters C, Arthur CP, Lin A, Porter J, Geeves MA, Milligan RA, et al. Myo1c is
831 designed for the adaptation response in the inner ear. *EMBO J.* 2004.
832 doi:10.1038/sj.emboj.7600169
- 833 29. Sun Y, Goldman YE. Lever-arm mechanics of processive myosins. *Biophysical*
834 *Journal.* 2011. doi:10.1016/j.bpj.2011.05.026
- 835 30. Sakamoto T, Yildez A, Selvin PR, Sellers JR. Step-size is determined by neck length
836 in myosin V. *Biochemistry.* 2005. doi:10.1021/bi0512086
- 837 31. Fréchal K, Polonais V, Marq JB, Stratmann R, Limenitakis J, Soldati-Favre D.
838 Functional dissection of the apicomplexan glideosome molecular architecture. *Cell*
839 *Host Microbe.* 2010;8: 343–357. doi:10.1016/j.chom.2010.09.002
- 840 32. Dominguez R, Freyzon Y, Trybus KM, Cohen C. Crystal structure of a vertebrate
841 smooth muscle myosin motor domain and its complex with the essential light chain:
842 Visualization of the pre-power stroke state. *Cell.* 1998. doi:10.1016/S0092-
843 8674(00)81598-6
- 844 33. Houdusse A, Szent-Györgyi AG, Cohen C. Three conformational states of scallop
845 myosin S1. *Proc Natl Acad Sci U S A.* 2000. doi:10.1073/pnas.200376897
- 846 34. Thomas DD, Kast D, Korman VL. Site-Directed Spectroscopic Probes of Actomyosin
847 Structural Dynamics. *Annu Rev Biophys.* 2009.

- 848 doi:10.1146/annurev.biophys.35.040405.102118
- 849 35. Pylypenko O, Houdusse AM. Essential “ankle” in the myosin lever arm. Proceedings
850 of the National Academy of Sciences of the United States of America. 2011.
851 doi:10.1073/pnas.1017676108
- 852 36. Logvinova DS, Levitsky DI. Essential Light Chains of Myosin and Their Role in
853 Functioning of the Myosin Motor. Biochemistry (Moscow). 2018.
854 doi:10.1134/S0006297918080060
- 855 37. Xie X, Harrison DH, Schlichting I, Sweet RM, Kalabokis VN, Szent-Györgyi AG, et al.
856 Structure of the regulatory domain of scallop myosin at 2.8 Å resolution. Nature. 1994.
857 doi:10.1038/368306a0
- 858 38. Houdusse A, Cohen C. Structure of the regulatory domain of scallop myosin at 2 Å
859 resolution: Implications for regulation. Structure. 1996. doi:10.1016/S0969-
860 2126(96)00006-8
- 861 39. Ni S, Hong F, Haldeman BD, Baker JE, Facemyer KC, Cremonese CR. Modification of
862 interface between regulatory and essential light chains hampers phosphorylation-
863 dependent activation of smooth muscle myosin. J Biol Chem. 2012.
864 doi:10.1074/jbc.M112.343491
- 865 40. Colson BA, Gruber SJ, Thomas DD. Structural dynamics of muscle protein
866 phosphorylation. Journal of Muscle Research and Cell Motility. 2012.
867 doi:10.1007/s10974-012-9317-6
- 868 41. Espinoza-Fonseca LM, Colson BA, Thomas DD. Effects of pseudophosphorylation
869 mutants on the structural dynamics of smooth muscle myosin regulatory light chain.
870 Mol Biosyst. 2014. doi:10.1039/c4mb00364k
- 871 42. Kast D, Espinoza-Fonseca LM, Yi C, Thomas DD. Phosphorylation-induced structural
872 changes in smooth muscle myosin regulatory light chain. Proc Natl Acad Sci U S A.
873 2010. doi:10.1073/pnas.1001941107
- 874 43. Houdusse A, Silver M, Cohen C. A model of Ca²⁺-free calmodulin binding to
875 unconventional myosins reveals how calmodulin acts as a regulatory switch.
876 Structure. 1996. doi:10.1016/S0969-2126(96)00154-2
- 877 44. Zhang Y, Kawamichi H, Kohama K, Nakamura A. Calcium-mediated regulation of
878 recombinant hybrids of full-length Physarum myosin heavy chain with
879 Physarum/scallop myosin light chains. Acta Biochim Biophys Sin (Shanghai). 2016.
880 doi:10.1093/abbs/gmw031
- 881 45. Lovett JL, Sibley LD. Intracellular calcium stores in *Toxoplasma gondii* govern
882 invasion of host cells. J Cell Sci. 2003. doi:10.1242/jcs.00596
- 883 46. Green JL, Rees-Channer RR, Howell SA, Martin SR, Knuepfer E, Taylor HM, et al.
884 The motor complex of *Plasmodium falciparum*: Phosphorylation by a calcium-
885 dependent protein kinase. J Biol Chem. 2008;283: 30980–30989.
886 doi:10.1074/jbc.M803129200
- 887 47. Nebl T, Prieto JH, Kapp E, Smith BJ, Williams MJ, Yates JR, et al. Quantitative in vivo
888 analyses reveal calcium-dependent phosphorylation sites and identifies a novel
889 component of the toxoplasma invasion motor complex. PLoS Pathog. 2011;7.
890 doi:10.1371/journal.ppat.1002222
- 891 48. Kawano Y, Fukata Y, Oshiro N, Amano M, Nakamura T, Ito M, et al. Phosphorylation
892 of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell
893 Biol. 1999. doi:10.1083/jcb.147.5.1023
- 894 49. Tang Q, Andenmatten N, Hortua Triana MA, Deng B, Meissner M, Moreno SNJ, et al.
895 Calcium-dependent phosphorylation alters class XIVa myosin function in the
896 protozoan parasite *Toxoplasma gondii*. Mol Biol Cell. 2014. doi:10.1091/mbc.E13-11-
897 0648
- 898 50. Treeck M, Sanders JL, Elias JE, Boothroyd JC. The phosphoproteomes of
899 *Plasmodium falciparum* and *Toxoplasma gondii* reveal unusual adaptations within and

- 900 beyond the parasites' boundaries. *Cell Host Microbe*. 2011;10: 410–419.
901 doi:10.1016/j.chom.2011.09.004
- 902 51. Fritz HM, Buchholz KR, Chen X, Durbin-Johnson B, Rocke DM, Conrad PA, et al.
903 Transcriptomic analysis of toxoplasma development reveals many novel functions and
904 structures specific to sporozoites and oocysts. *PLoS One*. 2012.
905 doi:10.1371/journal.pone.0029998
- 906 52. Borejdo J, Ushakov DS, Moreland R, Akopova I, Reshetnyak Y, Saraswat LD, et al.
907 The power stroke causes changes in the orientation and mobility of the termini of
908 essential light chain 1 of myosin. *Biochemistry*. 2001. doi:10.1021/bi002527u
- 909 53. Ridzuan MAM. Investigating GAP45 localisation and phosphorylation during
910 plasmodium falciparum schizont development. PhD Thesis, University College
911 London. 2012. Available from: <https://discovery.ucl.ac.uk/id/eprint/1354933/>
- 912 54. Savitsky P, Bray J, Cooper CDO, Marsden BD, Mahajan P, Burgess-Brown NA, et al.
913 High-throughput production of human proteins for crystallization: The SGC
914 experience. *J Struct Biol*. 2010. doi:10.1016/j.jsb.2010.06.008
- 915 55. Diebold ML, Fribourg S, Koch M, Metzger T, Romier C. Deciphering correct strategies
916 for multiprotein complex assembly by co-expression: Application to complexes as
917 large as the histone octamer. *J Struct Biol*. 2011. doi:10.1016/j.jsb.2011.02.001
- 918 56. Löw C, Neumann P, Tidow H, Weininger U, Haupt C, Friedrich-Epler B, et al. Crystal
919 structure determination and functional characterization of the metallochaperone SlyD
920 from thermus thermophilus. *J Mol Biol*. 2010. doi:10.1016/j.jmb.2010.03.014
- 921 57. Andrade MA, Chacón P, Merelo JJ, Morán F. Evaluation of secondary structure of
922 proteins from uv circular dichroism spectra using an unsupervised learning neural
923 network. *Protein Eng Des Sel*. 1993. doi:10.1093/protein/6.4.383
- 924 58. Whitmore L, Wallace BA. Protein secondary structure analyses from circular
925 dichroism spectroscopy: Methods and reference databases. *Biopolymers*. 2008.
926 doi:10.1002/bip.20853
- 927 59. Rozewicki J, Li S, Amada KM, Standley DM, Katoh K. MAFFT-DASH: integrated
928 protein sequence and structural alignment. *Nucleic Acids Res*. 2019.
929 doi:10.1093/nar/gkz342
- 930 60. Linding R, Jensen LJ, Diella F, Bork P, Gibson TJ, Russell RB. Protein disorder
931 prediction: Implications for structural proteomics. *Structure*. 2003.
932 doi:10.1016/j.str.2003.10.002
- 933 61. Kabsch W, Sander C. Dictionary of protein secondary structure: Pattern recognition of
934 hydrogen-bonded and geometrical features. *Biopolymers*. 1983.
935 doi:10.1002/bip.360221211
- 936 62. Cole C, Barber JD, Barton GJ. The Jpred 3 secondary structure prediction server.
937 *Nucleic Acids Res*. 2008. doi:10.1093/nar/gkn238
- 938 63. Blanchet CE, Spilotros A, Schwemmer F, Graewert MA, Kikhney A, Jeffries CM, et al.
939 Versatile sample environments and automation for biological solution X-ray scattering
940 experiments at the P12 beamline (PETRA III, DESY). *J Appl Crystallogr*. 2015.
941 doi:10.1107/S160057671500254X
- 942 64. Franke D, Petoukhov M V., Konarev P V., Panjkovich A, Tuukkanen A, Mertens HDT,
943 et al. ATSAS 2.8: A comprehensive data analysis suite for small-angle scattering from
944 macromolecular solutions. *J Appl Crystallogr*. 2017.
945 doi:10.1107/S1600576717007786
- 946 65. Panjkovich A, Svergun DI. CHROMIXS: Automatic and interactive analysis of
947 chromatography-coupled small-angle X-ray scattering data. *Bioinformatics*. 2018.
948 doi:10.1093/bioinformatics/btx846
- 949 66. Konarev P V., Volkov V V., Sokolova A V., Koch MHJ, Svergun DI. PRIMUS: A
950 Windows PC-based system for small-angle scattering data analysis. *J Appl*
951 *Crystallogr*. 2003. doi:10.1107/S0021889803012779

- 952 67. Svergun D, Barberato C, Koch MH. CRY SOL - A program to evaluate X-ray solution
953 scattering of biological macromolecules from atomic coordinates. *J Appl Crystallogr.*
954 1995. doi:10.1107/S0021889895007047
- 955 68. Petoukhov M V., Franke D, Shkumatov A V., Tria G, Kikhney AG, Gajda M, et al. New
956 developments in the ATSAS program package for small-angle scattering data
957 analysis. *J Appl Crystallogr.* 2012. doi:10.1107/S0021889812007662
- 958 69. Lundström P, Teilum K, Carstensen T, Bezsonova I, Wiesner S, Hansen DF, et al.
959 Fractional ¹³C enrichment of isolated carbons using [1-¹³C]- or [2-¹³C]-glucose
960 facilitates the accurate measurement of dynamics at backbone C α and side-chain
961 methyl positions in proteins. *J Biomol NMR.* 2007. doi:10.1007/s10858-007-9158-6
- 962 70. Teilum K, Brath U, Lundström P, Akke M. Biosynthetic ¹³C labeling of aromatic side
963 chains in proteins for NMR relaxation measurements. *J Am Chem Soc.* 2006.
964 doi:10.1021/ja055660o
- 965 71. Weininger U. Optimal Isotope Labeling of Aromatic Amino Acid Side Chains for NMR
966 Studies of Protein Dynamics. *Methods in Enzymology.* 2019.
967 doi:10.1016/bs.mie.2018.08.028
- 968 72. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: A
969 multidimensional spectral processing system based on UNIX pipes. *J Biomol NMR.*
970 1995. doi:10.1007/BF00197809
- 971 73. Johnson BA. Using NMRView to visualize and analyze the NMR spectra of
972 macromolecules. *Methods Mol Biol.* 2004.
- 973 74. Wittekind M, Mueller L. HNCACB, a High-Sensitivity 3D NMR Experiment to Correlate
974 Amide-Proton and Nitrogen Resonances with the Alpha- and Beta-Carbon
975 Resonances in Proteins. *Journal of Magnetic Resonance, Series B.* 1993.
976 doi:10.1006/jmrb.1993.1033
- 977 75. Grzesiek S, Bax A. Correlating Backbone Amide and Side Chain Resonances in
978 Larger Proteins by Multiple Relayed Triple Resonance NMR. *J Am Chem Soc.* 1992.
979 doi:10.1021/ja00042a003
- 980 76. Bax A, Clore GM, Gronenborn AM. ¹H¹H correlation via isotropic mixing of ¹³C
981 magnetization, a new three-dimensional approach for assigning ¹H and ¹³C spectra
982 of ¹³C-enriched proteins. *J Magn Reson.* 1990. doi:10.1016/0022-2364(90)90202-K
- 983 77. Grzesiek S, Anglister J, Bax A. Correlation of Backbone Amide and Aliphatic Side-
984 Chain Resonances in ¹³C/¹⁵N-Enriched Proteins by Isotropic Mixing of ¹³C
985 Magnetization. *Journal of Magnetic Resonance, Series B.* 1993.
986 doi:10.1006/jmrb.1993.1019
- 987 78. Yamazaki T, Forman-Kay JD, Kay LE. Two-Dimensional NMR Experiments for
988 Correlating ¹³C β and ¹H δ/ϵ Chemical Shifts of Aromatic Residues in ¹³C-Labeled
989 Proteins via Scalar Couplings. *Journal of the American Chemical Society.* 1993.
990 doi:10.1021/ja00076a099
- 991 79. Cornilescu G, Delaglio F, Bax A. Protein backbone angle restraints from searching a
992 database for chemical shift and sequence homology. *J Biomol NMR.* 1999.
993 doi:10.1023/A:1008392405740
- 994 80. Linge JP, Habeck M, Rieping W, Nilges M. ARIA: Automated NOE assignment and
995 NMR structure calculation. *Bioinformatics.* 2003. doi:10.1093/bioinformatics/19.2.315
- 996 81. Ferrage F, Piserchio A, Cowburn D, Ghose R. On the measurement of ¹⁵N-¹H
997 nuclear Overhauser effects. *J Magn Reson.* 2008. doi:10.1016/j.jmr.2008.03.011
- 998 82. Ferrage F, Cowburn D, Ghose R. Accurate sampling of high-frequency motions in
999 proteins by steady-state ¹⁵N-¹H nuclear overhauser effect measurements in the
1000 presence of cross-correlated relaxation. *J Am Chem Soc.* 2009.
1001 doi:10.1021/ja809526q
- 1002 83. Weininger U, Diehl C, Akke M. ¹³C relaxation experiments for aromatic side chains
1003 employing longitudinal-and transverse-relaxation-optimized NMR spectroscopy. *J*

- 1004 Biomol NMR. 2012. doi:10.1007/s10858-012-9650-5
- 1005 84. Kabsch W. 1 XDS. Acta Crystallogr Sect D. 2010. doi:10.1107/s0907444909047337
- 1006 85. Evans PR, Murshudov GN. How good are my data and what is the resolution? Acta
1007 Crystallogr Sect D Biol Crystallogr. 2013. doi:10.1107/S0907444913000061
- 1008 86. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.
1009 Phaser crystallographic software. J Appl Crystallogr. 2007.
1010 doi:10.1107/S0021889807021206
- 1011 87. Sheldrick GM. A short history of SHELX. Acta Crystallographica Section A:
1012 Foundations of Crystallography. 2008. doi:10.1107/S0108767307043930
- 1013 88. Adams PD, Afonine P V., Bunkóczy G, Chen VB, Davis IW, Echols N, et al. PHENIX:
1014 A comprehensive Python-based system for macromolecular structure solution. Acta
1015 Crystallogr Sect D Biol Crystallogr. 2010. doi:10.1107/S0907444909052925
- 1016 89. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by
1017 the maximum-likelihood method. Acta Crystallographica Section D: Biological
1018 Crystallography. 1997. doi:10.1107/S0907444996012255
- 1019 90. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta
1020 Crystallogr Sect D Biol Crystallogr. 2010. doi:10.1107/S0907444910007493
- 1021 91. Krissinel E, Henrick K. Inference of Macromolecular Assemblies from Crystalline
1022 State. J Mol Biol. 2007. doi:10.1016/j.jmb.2007.05.022
- 1023 92. Webb B, Sali A. Comparative protein structure modeling using MODELLER. Curr
1024 Protoc Bioinforma. 2016. doi:10.1002/cpbi.3
- 1025 93. Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, et al. UCSF
1026 ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci.
1027 2018. doi:10.1002/pro.3235
- 1028 94. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, et al. Scalable
1029 molecular dynamics with NAMD. Journal of Computational Chemistry. 2005.
1030 doi:10.1002/jcc.20289
- 1031 95. Bahar I, Lezon TR, Bakan A, Shrivastava IH. Normal mode analysis of biomolecular
1032 structures: Functional mechanisms of membrane proteins. Chem Rev. 2010.
1033 doi:10.1021/cr900095e
- 1034 96. Grant BJ, Rodrigues APC, ElSawy KM, McCammon JA, Caves LSD. Bio3d: An R
1035 package for the comparative analysis of protein structures. Bioinformatics. 2006.
1036 doi:10.1093/bioinformatics/btl461
- 1037 97. Laskowski RA, MacArthur MW, Thornton JM. PROCHECK : validation of protein-
1038 structure coordinates . 2012. doi:10.1107/97809553602060000882
- 1039 98. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al.
1040 MolProbity: More and better reference data for improved all-atom structure validation.
1041 Protein Sci. 2018. doi:10.1002/pro.3330
- 1042

1043 **List of abbreviations**

1044	Complex 1	trimeric complex of TgELC1, TgMyoA-C and MLC1-S with bound calcium ion
1045		
1046	Complex 1f	trimeric complex of TgELC1, TgMyoA-C and MLC1-S, calcium-free
1047		
1048	Complex 2	trimeric complex of TgELC2, TgMyoA-C and MLC1-S with bound calcium ion
1049		
1050	ELC	essential light chain
1051	GAC	glideosome associated connector
1052	GAP	glideosome associated protein
1053	GAPM	glideosome associated protein with multiple membrane spans
1054	IMC	inner membrane complex
1055	MIC1	microneme protein 1
1056	MLC1	myosin light chain 1
1057	MLC1-S	short construct of protein myosin light chain 1, residues 66-210
1058	MTIP	myosin A tail interacting protein
1059	MTIP-S	short construct of protein myosin A tail interacting protein, residues 60-204
1060		
1061	MyoA	myosin A
1062	SAXS	small angle X-ray scattering
1063	SEC	size exclusion chromatography
1064	TgMyoA-C	C-terminal construct of <i>T. gondii</i> myosin A, residues

1065 **Figure captions:**

1066 **Fig 1. Glideosome and myosin light chains.** (A) Schematic representation of the current
1067 model of the glideosome and its localization in the parasite's intermembrane space. Actin is
1068 immobilized to the plasma membrane whereas myosin A is part of the glideosome, which
1069 binds the essential light chains ELC and myosin light chain MLC1 (called myosin tail
1070 interacting protein, MTIP, in *Plasmodium spp.*). Myosin A and its light chains further interact
1071 with glideosome associated proteins GAP40, GAP45 and GAP50, which anchor the
1072 glideosome in the outer membrane of the inner membrane complex. (B) Schematic
1073 representation of the myosin light chain constructs used in this study. The numbers indicate
1074 the sequence residues of the particular protein; the scissor symbol represents a TEV cleavage
1075 site. (C) Sequence alignment of *P. falciparum* PfELC and *T. gondii* TgELC1 and TgELC2.
1076 Identical residues between these proteins are highlighted in red. The boxed residues indicate
1077 the residues involved in the polar interactions with TgMyoA (see Fig 5 and S4 Table).
1078 Secondary structure elements of PfELC as predicted by JPred are graphically shown under
1079 the sequence alignment.

1080 **Fig 2. Structural differences between ELCs of *T. gondii* and *P. falciparum*.** (A) Gel
1081 filtration profile of PfELC (red) and TgELC2 (blue) on a home-packed Superdex 200 5/150
1082 column. PfELC elutes at a smaller elution volume, suggesting that it has a larger hydrodynamic
1083 radius compared to TgELC2. (B) Far-UV-circular dichroism spectrum of PfELC (red) and
1084 TgELC2 (blue) shows that PfELC has a lower α -helical and higher random coil content
1085 compared to TgELC2. (C) Backbone dynamics of PfELC on a picosecond to nanosecond time
1086 scale. Heteronuclear NOE ($\{^1\text{H}\}$ - ^{15}N NOE) of PfELC on a residue basis. Residues are colored
1087 according to secondary structure elements (four α -helices: from N terminus red, orange, violet,
1088 cyan, random coil/loop residues are green, unassigned C-terminal residues in grey). (D)
1089 Experimental small angle X ray scattering curve of PfELC (red) and calculated scattering
1090 (black line) from the crystal structure of the PfELC monomer fit with a X^2 value of 1.37,
1091 confirming that the protein is a structurally rigid globular monomer in solution. (E) Crystal

1092 structure of the N-terminal isolated domain of PfELC, residues 1-68. PfELC displays a typical
1093 calmodulin fold with two helix-loop-helix motifs. The degenerate EF hand loops do not bind
1094 any ion. In agreement with NMR data of full length PfELC, the protein consists of four α -helices
1095 (from N terminus red, orange, violet, cyan, loops and disordered regions in green). The termini
1096 are labelled. (F) Ten lowest-energy NMR structures of PfELC (residues 1-74) colored from
1097 lowest (blue) to highest (red) backbone RMSD compared to the crystal structure show that the
1098 loop of the PfELC first EF hand (residues 16-22) and the third helix (residues 40-47) display a
1099 certain degree of flexibility.

1100 **Fig 3. Formation of trimeric complexes between ELC, MLC1 (MTIP) and the MyoA**
1101 **C-terminus.** (A) Sequence comparison of TgMyoA and PfMyoA C-termini shows a conserved
1102 region (green arrow) upstream of the MLC1 (MTIP) binding site. Whereas two binding sites of
1103 PfELC at the very C-terminus of PfMyoA were proposed (black arrows) [14], our data show
1104 that the actual binding site of PfELC encompasses the MyoA conserved region and is similar
1105 to the TgELC/TgMyoA binding site (blue arrows). The blue boxed residues indicate residues
1106 involved in polar interactions with TgELC1 and TgELC2, while yellow boxed residues form
1107 polar interactions with MLC1 (see Fig 5C-D and S4 Table). (B) The peptide constructs
1108 representing the C-terminal regions of MyoAs with indicated domain borders used in this
1109 study. The constructs PfMyoA-C and TgMyoA-C encompass both MLC1/MTIP binding sites
1110 as well as the upstream conserved region which binds the essential light chains. The construct
1111 TgMyoA-C^{ELC} only consists of the TgELC binding site. (C,D) Isothermal titration of
1112 TgMyoA-C^{ELC} with TgELC1 and TgELC2 show that both dimeric complexes form with
1113 nanomolar affinity. The upper panel shows the signal recorded directly after each injection of
1114 TgELC1 and TgELC2 and represents the thermal power that has to be applied to maintain a
1115 constant temperature in the sample cell during recurring injections. In the lower panel, the
1116 integrated heats are plotted against the peptide/protein concentration ratio. The
1117 thermodynamic binding parameters were obtained by nonlinear regression of the experimental
1118 data using a one-site binding model. (E) Binding isotherm of PfELC titrated to the preformed

1119 MTIP/PfMyoA-C complex proves that the conserved hydrophobic region of MyoAs is
1120 indispensable for ELC binding. (G,H) Binding isotherms of MLC1 titrated into the pre-complex
1121 of TgMyoA-C with TgELC1 and TgELC2. MLC1 binds the pre-complex with high nanomolar
1122 affinity. All thermodynamic parameters derived from ITC measurements are summarized in
1123 Table 3.

1124 **Fig 4. Both TgELCs and TgMyoA undergo large conformational changes upon binding.**

1125 (A) Dimeric complex of TgELC2 and TgMyoA-C elutes at shorter retention times than isolated
1126 TgELC2 on a home-packed Superdex 200 5/150 column, suggesting that the hydrodynamic
1127 radius of TgELC2 decreases upon TgMyoA-C binding. (B) Kratky plots of isolated TgELC2
1128 and in complex with TgMyoA-C. The dimensionless Kratky plot of TgELC2 in complex with
1129 TgMyoA-C^{ELC} (black) has a maximum close to $sR_g = \sqrt{3}$ and converges to zero, unlike isolated
1130 TgELC2 (blue), suggesting that TgELC2 in isolation is rather extended and compacts upon
1131 binding to TgMyoA. (C) The distance distribution calculated by Guinier analysis from the SAXS
1132 data further confirms that TgELC2 undergoes compaction upon TgMyoA binding. TgELC2
1133 displays wider distance distribution with $d_{max} = 6.7$ nm, whereas the distance distribution of the
1134 dimeric complex is narrower with $d_{max} = 5.5$ nm. (D) The far-UV CD data indicate that TgELC2
1135 induces a α -helical structure in TgMyoA upon binding. The individual spectra of TgELC2 and
1136 TgMyoA-C^{ELC} do not sum up to the CD spectrum of their dimeric complex and the CD spectrum
1137 of the dimeric complex displays more pronounced features of α -helical secondary structure
1138 with lower ellipticity at 222 nm and higher ellipticity at 195 nm compared to the sum of
1139 individual components. CD spectra were recorded in a 1 mm cuvette at a concentration of
1140 5 μ M of each component in 10 mM NaP (pH 7.5), 150 mM NaF and 0.25 mM TCEP at 20°C.

1141 **Fig 5. Crystal structures of glideosome trimeric complexes.** (A) Crystal structures of

1142 trimeric complex of TgELC1 (green), TgMyoA-C (pink) and MLC1 (orange) (complex 1). (B)
1143 Crystal structure of trimeric complex of TgELC2 (blue), TgMyoA-C (pink) and MLC1 (orange)
1144 (complex 2). The complex structures with TgELC1 and TgELC2 are very similar and the
1145 TgMyoA helix displays a characteristic kink between residues 801-803. ELCs bind upstream

1146 of the MLC1 binding site. (C,D) Binding interface between TgMyoA-C (pink) and TgELC1
1147 (green) in complex 1 and TgELC2 (blue) in complex 2. Residues involved in polar interactions
1148 are labelled with the corresponding colour and shown in stick representation. Most polar
1149 interactions are mediated by C-terminal lobes of TgELCs and the hydrophobic interactions
1150 between TgELCs and the conserved hydrophobic TgMyoA residues play a crucial role in
1151 complex formation as evident from ITC measurements. (E) Experimental small angle X-ray
1152 scattering curve of TgELC2 bound to TgMyoA-C^{ELC} (blue). The fit to the scattering pattern
1153 computed from the crystal structure of complex 2 omitting MLC1 (black line, $\chi^2 = 1.16$) shows
1154 that TgELC2 does not undergo major conformational changes upon binding of MLC1 and the
1155 formation of the trimeric complex. (F) SAXS analysis of the different trimeric complexes.
1156 Similarity of the scattering profiles indicates a similar shape for all three complexes, suggesting
1157 that the architecture of the trimeric complexes is conserved between *T. gondii* and
1158 *P. falciparum*. Computed scattering curves of complex 1 and complex 2 fit the respective
1159 experimental data with $\chi^2 = 1.26$ and $\chi^2 = 2.41$, respectively. (G) The distance distribution plots
1160 of complex 1 calculated from experimental small angle X ray scattering data change by
1161 shortening the MLC1 N-terminal domain, indicating flexibility of MLC1 upstream of residue 77.
1162 The distance distribution is narrower upon N-terminal truncation of MLC1, with d_{max} decreasing
1163 from 14 nm (complex 1 with full-length MLC1¹⁻²¹³) to 9.5 nm (MLC1⁶⁶⁻²¹⁰) and further to 8.2 nm
1164 (MLC1⁷⁷⁻²¹⁰).

1165 **Fig 6. Influence of calcium on complex formation.** (A) Crystal structure of the glideosome
1166 trimeric complex composed of TgELC1 (green), MLC1 (orange) and TgMyoA-C (pink) in the
1167 absence of calcium (complex 1f). The absence of calcium does not cause a major structural
1168 rearrangement (see Fig 5A). (B) Structural comparison of the first EF hand in ELCs and
1169 calcium coordination between complex 1f, complex 1, complex 2 and PfELC-N. Whereas
1170 PfELC does not bind any ion due to a degenerate sequence in its EF hand, both TgELCs in
1171 complex 1 and complex 2 bind calcium in a tetragonal bipyramid coordination, including two
1172 water molecules. These water molecules are further stabilized in complex 2 by additional

1173 residues (E27, Q49, D20). In complex 1f, the side chain of residue D17 is flipped by 120°,
1174 enabling the release of calcium. (C) Thermal stability of the dimeric complex of TgMyoA-C and
1175 wild type TgELC2 or its mutant TgELC2^{D16A} shows that the mutant TgELC2^{D16A} loses its ability
1176 to bind calcium but is also substantially less stable. (D-F) Binding interfaces between TgELCs
1177 and MLC1 in the trimeric complex structures of (from left) complex 1f, complex 1 and complex
1178 2. Corresponding residues are labelled with the respective colour. The same set of residues
1179 (K168, Q169, N172, Y177) is involved in polar interactions (indicated by yellow dashes) on
1180 the MLC1 site, but various residues are utilized by TgELCs. (G-H) Thermal stability change of
1181 trimeric complex 1 and complex 2 upon addition of calcium measured by nanoDSF. The
1182 stability of both complexes strongly increases upon calcium binding.

1183 **Fig 7. Trimeric complexes modelled in the full-length MyoA context.** (A)
1184 Energy-minimized model of complex 1 as a part of TgMyoA. (B) Energy-minimized model of
1185 complex 2 as a part of TgMyoA. The models show that the crystal structures of the trimeric
1186 complexes are compatible with the structure of TgMyoA and maintain the α -helical structure
1187 of the TgMyoA lever arm. No clashes between TgMyoA and TgELCs were observed. (C)
1188 Deformation analysis of complex 2 identified two hinge regions in the lever arm of myosin A,
1189 which contribute to most of the observed dynamics of the protein complex within the 20
1190 lowest-energy modes. The model is coloured by deformation energy from lowest (violet) to
1191 highest (red). The hinges localize to the TgMyoA lever arm between the converter domain and
1192 the TgELC2 binding site (hinge 1, residues 773-777) as well as between the TgELC2 and
1193 MLC1 binding sites (hinge 2, residues 799-801). These deformations agree with the role of
1194 TgMyoA in the pre-power stroke state in the context of a power stroke cycle, where the myosin
1195 is probing the conformational space to bind to actin.

1196

1197 **Supporting information captions**

1198 **S1 Figure. A** Disorder probability prediction calculated by the disEMBL server shows
1199 differences between PfELC and TgELCs, predominantly in the C-terminal region of the

1200 sequence. The disorder for the prediction was defined by dictionary of secondary structure
1201 probabilities. The amino acid residues with disorder probability above the threshold (dashed
1202 line) are predicted to be disordered. **B** Recorded SAXS curves of isolated PfELC and TgELC2
1203 indicate conformational differences of these homologous proteins. **C** The dimensionless
1204 Kratky plot shows that TgELC2 is more compact than PfELC. Although none of the plots
1205 converges to zero, the maximum of TgELC2 is considerably closer to $sR_g = \sqrt{3}$ compared to
1206 PfELC. **D** Elution profile of on-line SEC-SAXS measurement of PfELC using a Superdex 200
1207 5/150 column with the region used for the analysis highlighted in grey. **E** Overlay of ^{15}N HSQC
1208 spectra of full-length PfELC (red) and its N-terminal construct PfELC-N (black), indicating that
1209 the construct PfELC-N is identical to the N-terminal domain of full-length PfELC. Assigned
1210 resonances are labeled. **F** Dimer of PfELC-N formed by a cysteine bond between two
1211 symmetry related molecules. **G** SDS-PAGE gel with PfELC-N samples dialyzed against
1212 buffers with varying concentration of TCEP and subsequently alkylated by 2-iodoacetamide.
1213 The results show that the protein is monomeric with the concentration of TCEP used for its
1214 biophysical characterization.

1215 **S2 Figure.** ITC binding isotherm of PfMyoA-C titrated into MTIP measured at 25°C.

1216 **S3 Figure. A** Small Angle X-ray scattering profiles of TgELC2 (blue) and in complex with
1217 TgMyoA-C (black) show conformational changes upon interaction. **B** Elution profile of on-line
1218 SEC-SAXS measurement of TgELC2 using a Superdex 200 10/300 column with the region
1219 used for the analysis highlighted in grey. **C** Far-UV CD spectra of both PfMyoA-C (pink) and
1220 TgMyoA-C (violet) indicate that the unbound C-terminus of MyoA is disordered (TgMyoA) or
1221 partially disordered (PfMyoA). **D** Far-UV CD data indicate that TgELC1 induces α -helical
1222 structure in TgMyoA upon binding. The individual spectra of TgELC1 (green) and TgMyoA^{ELC}
1223 (pink) do not sum up (dotted black line) to the spectrum of their dimeric complex (black
1224 continuous line), which has more pronounced features of α -helical secondary structure with
1225 lower ellipticity at 222 nm and higher ellipticity at 195 nm. The data were collected in a 1 mm

1226 cuvette at a concentration of 5 μ M of each component in 10 mM NaP (pH 7.5), 150 mM NaF
1227 and 0.25 mM TCEP at 20°C.

1228 **S4 Figure. A** Isothermal titration calorimetry of TgELC2 mutants binding to TgMyoA-C^{ELC}.
1229 Individual mutations of polar residues (E10A, F79A, S101A) of TgELC2 interacting with
1230 TgMyoA-C^{ELC} do not cause major changes in the affinity of the two components, but the double
1231 mutant TgELC2E10A+H110A shows a threefold lower affinity. **B-C** Overlay of MLC1 derived
1232 from the published dimeric complex structure in grey (PDB ID 5vt9, orange) with the protein
1233 chains of the trimeric complex structures (complex 1 on the left and complex 2 on the right)
1234 shows that MLC1 does not undergo any major structural changes upon TgELC1 or TgELC2
1235 binding. Color code of MLC1 derived from the trimeric complexes according to RMSD
1236 deviation of C α is indicated. **D** Experimental small angle X ray scattering curves of complex 2
1237 with the short MLC1 construct (MLC1⁷⁷⁻²¹⁰) and full-length MLC1 (MLC1¹⁻²¹⁰). The calculated
1238 scattering curve computed from the crystal structure of complex 1 fits the scattering data of
1239 complex 1 with construct MLC1⁷⁷⁻²¹⁰ with $\chi^2 = 1.04$, suggesting that MLC1 residues 77-210
1240 form a folded and rigid entity in the complex. The experimental data of complex 1 with full
1241 length MLC1¹⁻²¹³ fit the calculated scattering data from the crystal structure of complex 1 and
1242 N-terminal MLC1 residues modelled by CORAL with $\chi^2 = 1.15$.

1243 **S5 Figure. A** Comparison of far-UV circular dichroism spectra of individual ELC proteins in
1244 presence and absence of calcium ions show that calcium does not significantly alter the
1245 secondary structure of the ELCs. **B** Binding isotherms of MyoA-C titrated to the TgELC2
1246 mutant D16A (first calcium-binding EF hand) shows that calcium does not have a major
1247 influence on the affinity of TgELC2 to the myosin A neck. **C** ITC binding isotherms of MLC1
1248 titrated to the TgELC2/TgMyoA-C pre-complex. TgELC2 or MLC1 residues forming the
1249 binding interface were mutated individually and their affinity was measured to assess the
1250 contribution to the binding interface within the trimeric complex. The measured mutants were
1251 TgELC2 mutants R17A and E22A, and MLC1 mutants K168A, Q169A and N172A. The
1252 binding affinities were in the low nanomolar range. **D** Stability dependence of the trimeric

1253 complex upon addition of increasing concentrations of calcium illustrated by the increase in
1254 T_M ($^{\circ}\text{C}$). Stability data for complex one are shown on the left and for complex two on the right.
1255 The colored points are individual measurements and “+” represents the average. The
1256 experiment shows that the stability of the trimeric complex is greatly enhanced by the addition
1257 of calcium in a concentration-dependent manner.

1258 **S6 Figure. A** Summary plot of the atomic displacements predicted by NMA based on the five
1259 lowest-energy models for complex 2 selected by the lowest clash score. The relative atomic
1260 displacement of the individual amino acid residues follows the same pattern in all five models,
1261 confirming that the results of the normal mode analysis are independent of the chosen starting
1262 conformation or the energy-minimized model. The results for complex 1 are similar (data not
1263 shown). **B** The deformation analysis of complex 1 averaged through the 20 lowest-energy
1264 modes predicts two main hinge regions, with the hinge 1 (residues 773-777), having the
1265 largest contribution to the observed motions. The model is coloured by the deformation energy
1266 from low (violet) to high (red). **C** The ensemble of the structures of complex 2 based on the
1267 two lowest-energy modes, which contribute most to the large-scale dynamics of proteins. The
1268 original model is drawn in cartoon representation with shown semitransparent surface,
1269 whereas the deformed structures are partially transparent and drawn in ribbon representation
1270 with faded surface. The structures were aligned on MLC1 to reflect the immobilization of MLC1
1271 in the IMC membrane as in the current model of the glideosome (see Fig 1A).


1272 **S1 Table. A list of published *P. falciparum* and *T. gondii* glideosome protein structures**
1273 **published.** So far, only the structures of individual proteins of glideosome and two
1274 homologous subcomplexes (MTIP/PfMyoA and MLC1/TgMyoA) have been solved.

1275 **S2 Table. SAXS sample details, data acquisition parameters, structural parameters and**
1276 **atomistic modelling.**


1277 **S3 Table. Statistics for NMR structure calculation of PfELC (residues 1-74).**
1278 Ramachandran analysis was performed by PROCHECK [97].

1279 **S4 Table. Polar interactions in the structures of the trimeric complexes inspected by**
1280 **Molprobit [98].**

A



B



C




Figure 1




Figure 2






Figure 3


A




B



C



D






Figure 5





Figure 6

A



- MLC1
- TgELC1
- TgELC2
- TgMyoA lower 50 kDa domain

B



- TgMyoA lever arm helix
- TgMyoA converter domain
- TgMyoA N-terminal domain
- TgMyoA upper 50 kDa domain

C




Figure 7